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Abstract 
Chronic stress is associated with elevated levels of sympathetic neurotransmitter 
release and immunosuppression. A growing body of evidence suggests that stress-related 
factors may contribute to the initiation, development and progression of breast cancer. 
Neuropeptide Y (NPY) has recently been determined as such a factor, however few 
investigations have addressed the functional effects of NPY on breast cells and tumors. 
Thus, the overall objective of this thesis was to elucidate the mechanisms by which NPY 
may contribute to the disease. Using the 4T1 murine breast cancer model, we began by first 
characterizing NPY receptor expression in cancer cells and tumors. Y1R, Y2R and Y5R’s 
were expressed in 4T1 cells and tumors. In vitro assays were then conducted to determine 
the effects of NPY receptor activation on 4T1 cell proliferation and migration. NPY treatment 
of 4T1 cells stimulated Y5R mediated increases in proliferation, whereas, NPY increased 
chemotaxis through Y2R and Y5R activation. We then tested whether NPY could function as 
an angiogenic factor by augmenting expression and secretion of the pro-angiogenic factor 
VEGF from breast cancer cells. We found that NPY functioned as a paracrine system within 
4T1 and MDA-MB-231 cancer cells to promote angiogenesis, signaling to increase 
expression and release of VEGF through Y5R activation. These findings served as a 
motivation for our final study where we sought to develop an in vivo model in which the 
components of NPY system (i.e., nerves, ligands and receptors) could be functionally 
studied. We first demonstrated sympathetic neural innervation and NPY expression in 4T1 
tumors. Secondly, when tumor sympathetic neural innervation was attenuated (via chemical 
sympathectomy), we observed a significant decrease in tumor growth and vascular 
development. Furthermore, we observed that treatment with a Y5R antagonist significantly 
attenuated tumor growth. Finally, we established a protocol for intravital microscopy imaging 
of tumoral vasculature. Overall, this dissertation provides: 1) evidence that NPY elicits 
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proliferative, migratory and angiogenic effects on breast cancer cells, 2) an in vivo model for 
functional studies examining the role of sympathetic nerves, neurotransmitters, cancer cells 
and blood vessels, and 3) highlights the Y5R as a potential therapeutic target. 
Keywords: neuropeptide Y, sympathetic nervous system, breast cancer, 4T1 murine breast 
cancer, proliferation, chemotaxis, angiogenesis, Y1-receptor, Y2- receptor, Y5-receptor 
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Preface 
 
“The mind is not a vessel to be filled but a fire to be kindled.” 
   Plutarch 
    
 
 
“If you don’t know, now you know…” 
   Christopher Wallace 
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Chapter 1  
1 Introduction 
1.1 General Introduction 
 Breast cancer is the most frequently diagnosed cancer among females, affecting 
thousands of women each year. In 2012 an estimated 22,700 will be diagnosed, and 
5,100 will die from breast cancer in Canada (Society, 2012) Death rates have declined 
significantly over the past thirty years due to extensive research, as well as more 
frequent and advanced breast screening programs in Canada. Nonetheless, many of the 
underlying mechanisms that drive the progression of this disease remain to be 
understood.  
 Stress has long been thought to be associated with the development of and 
progression of cancer. Epidemiological studies have correlated elevated stress with poor 
prognosis and/or survival in cancer patients (Ben-Eliyahu, 2003). From a physiological 
context, daily stressors (e.g., physical, psychological, and/or physiological) are known to 
cause an activation of the sympathetic nervous system (SNS) or “Fight or Flight” 
response. The SNS responds rapidly through increased neural activation, which 
releases the neurotransmitters norepinephrine (NE), neuropeptide Y (NPY), and 
adenosine triphosphate (ATP) to act on associated receptors in the heart, peripheral 
vasculature and other organs. Acutely, this neural response is essential to regulating 
cardiovascular and immune function, and maintaining homeostatic balance. However, 
chronically elevated SNS activity observed during stress can be problematic in a 
pathologies such as cancer. Tissues such as the breast, that are densely innervated by 
sympathetic nerves, may become exposed to heightened levels of NE, NPY, and ATP, 
thus potentially stimulating deleterious mitogenic, chemotaxic and angiogenic effects on 
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cancer development and progression (Cole & Sood, 2012; Ruscica, Dozio, Motta, & 
Magni, 2007). Interestingly, women with family histories of breast cancer have been 
reported to have greater sympathetic neurotransmitter release (measured in urine 
samples) in response to daily stressors (James, Berge-Landry Hv, Valdimarsdottir, 
Montgomery, & Bovbjerg, 2004).  
Sympathetically mediated immunosuppression was initially postulated as the 
mechanism linking stress to cancer progression. The immune system is intimately 
regulated by the SNS through innervation of the bone marrow, thymus, spleen and 
lymph nodes (Bellinger, et al., 2008; Elenkov, Wilder, Chrousos, & Vizi, 2000; Levite, 
2000). Acute sympathetic activation can promote immune responses such as 
inflammation; however, past studies have also shown that elevated levels of 
norepinephrine can suppress lymphocyte functions such as T-cell proliferation and 
antigen presentation (Inbar, et al., 2011; Shakhar & Ben-Eliyahu, 1998). As such, 
heightened sympathetic neurotransmitter release has been associated with a 
suppressed immune response during primary tumor development and metastasis. 
Recent studies have demonstrated that sympathetic neurotransmitters (NE and 
NPY) may also have direct effects on cancerous cells (Medeiros, et al., 2012; Sheriff, et 
al., 2010; Thaker, et al., 2006). NE activating β-adrenergic receptors has been shown to 
promote cell growth, stimulate tumor angiogenesis and increase the incidence of 
metastasis in breast, prostate and ovarian cancers (Palm, et al., 2006; Sloan, et al., 
2010; Thaker, et al., 2006). The functional impact of NPY on cancer cells has been a 
question of growing interest. NPY functions by activating a group of six G protein-
coupled receptors (Y1R-Y6R) of which the Y1R, Y2R and Y5R are most abundantly 
expressed in humans, and have been most extensively studied. NPY receptors have 
been reported in several types of cancer, including neural crest tumors (i.e., 
3 
 
neuroblastomas and pheochromocytomas) and epithelial malignancies such as ovarian, 
prostate and breast cancer (Kitlinska, et al., 2005; Kogner, Bjork, & Theodorsson, 1993; 
Korner & Reubi, 2008; Korner, Waser, & Reubi, 2004; Magni & Motta, 2001; Reubi, 
Gugger, Waser, & Schaer, 2001). Activation of NPY receptors has been reported to 
have receptor subtype and cancer-specific responses. Limited studies have 
demonstrated that NPY may cause proliferation or apoptosis, migration, and 
angiogenesis in different types of cancer. It has been suggested that NPY receptor 
activation may be involved in breast cancer progression by stimulating proliferation of 
breast cancer cells, and promoting angiogenesis (Korner & Reubi, 2007), however these 
postulates have yet to be confirmed in vivo. 
Human xenografts in immunocompromised mice are commonly used to study 
primary tumor growth and metastasis. Syngeneic mouse models provide an 
immunocompetent model in which tumor cell-host interactions and metastatic patterns 
parallel those observed in cancer patients (Prewett, et al., 1999). The 4T1 murine 
mammary cancer cell line is a well-established model of breast cancer that been used 
extensively to study anti-metastatic and anti-angiogenic therapies in syngeneic models 
(Lin, et al., 1998; Prewett, et al., 1999). However, to date, the components of the NPY 
system (nerves, ligand and receptors), and/or the functional response of NPY have yet 
to be characterized in any sygeneic breast cancer model.   
 
1.2 4T1 Breast Cancer Model 
The 4T1 cell line originated from a spontaneously arising BALB/c mammary tumor 
(Pulaski & Ostrand-Rosenberg, 2001). It is a highly tumorigenic and invasive cell line 
that can spontaneously metastasize from the primary orthotopic mammary tumor to 
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multiple secondary sites such as the lymph nodes, lungs, liver, blood, brain and bone 
(Pulaski & Ostrand-Rosenberg, 2001; Tao, Fang, Alroy, & Sahagian, 2008). 
Orthotopically implanted 4T1 tumors grow rapidly, and will metastasize from the primary 
site over a period of 3-6 weeks. Given the rapid and efficient metastatic pattern that has 
been observed with the 4T1 model, it has become a commonly used model in the study 
of metastatic progression of breast cancer in humans (Pulaski & Ostrand-Rosenberg, 
2001; Tao, et al., 2008). Moreover, since it is of a syngeneic cell line in BALB/c mice, 
tumor growth and metastasis can be studied in the presence of an intact immune 
system, and as such, this mouse model closely parallels the human condition. 
1.2.1 Sympathetic Neural Transmission 
The SNS is a branch of the autonomic nervous system, which innervates the 
heart, vasculature and viscera (Robertson, 2004). It is the body’s primary neural 
responder to acute internal or external stresses by increasing its neurotransmitter 
release centrally (i.e., viscera) and to the peripheral vasculature (Robertson, 2004). 
Sympathetic nerve fibers originate in the lateral horns of the thoracic and lumbar spinal 
regions (T1-L2) (Robertson, 2004). Preganglionic myelinated fibers branch off the spine 
as white rami, which then enter the sympathetic ganglia. In the ganglia presynpatic 
neurons synapse with postganglionic neurons (Robertson, 2004). Neural transmission 
between pre and post fibers occurs by the release of acetylcholine (ACh) from 
preganglionic fibers, which then binds to nicotinic receptors of postganglionic fibers 
(Robertson, 2004). Sympathetic transmission concludes with the postganglionic release 
of sympathetic neurotransmitters: NE, NPY, ATP, met-enkephalin, substance P, 
bombesin and dopamine, of which NE, NPY and ATP predominate (Robertson, 2004). 
These neurotransmitters will then bind to their respective receptors located on the target 
tissue. The breast receives sympathetic innervation from nerves arising from the lateral 
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and anterior cutaneous branches of the second to sixth intercostal nerves (Fischer & 
Bland, 2007). These nerves provide a constant supply of sympathetic neurotransmitters 
to the mammary gland, smooth muscle of the areola, skin and breast blood vessels 
(Fischer & Bland, 2007) 
1.2.2 Catecholamines 
Catecholamines are amines that are structurally characterized by a benzene ring, 
two hydroxyl groups, an intermediate ethyl chain, and a terminal amine group. In 
humans the most abundantly synthesized and released are epinephrine (EP), NE and 
dopamine. Chromaffin cells of the adrenal medulla produce EP and NE, peripheral 
postganglionic neurons synthesize NE, and dopamine is found in the central nervous 
system, functioning as a neurotransmitter in the brainstem. In the periphery, the uptake 
of L-tyrosine by postsynaptic nerve terminals is the first step in catecholamine synthesis 
(Nagatsu, Levitt, & Udenfriend, 1964). L-tyrosine is then converted to L-
dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase (TH). This 
conversion represents the rate-limiting step in the biosynthesis of catecholamines 
(Udenfriend, 1966). As such, the production of NE acts to inhibit the production of TH via 
a negative feedback reaction (Nagatsu, et al., 1964), whereas a stress induced increase 
in sympathetic nerve activity will cause an increase in TH (Wong & Tank, 2007). L-
aromatic-amino-acid decarboxylase (L-AADC) then catalyzes the conversion of L-DOPA 
to dopamine. In peripheral nerve terminals and chromaffin cells, Dopamine-β-
hydroxylase (DBH) localized in large dense-core vesicles, converts dopamine to NE, 
which then remains in the synaptic vesicles until exocytosis occurs and they are 
released into the synaptic cleft.   
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1.3 Neuropeptide Y 
Until recently, only the effects of NE on cancer progression had been examined. 
Accumulating data has now illustrated functional implications of NPY and its respective 
receptors to the progression of this disease. NPY is the most abundantly expressed 
peptide of the pancreatic polypeptide family in mammalian systems, exhibiting 
pleiotropic actions throughout the body. The 36-amino acid peptide is most widely 
expressed in the central and peripheral nervous systems, playing major roles in 
cognitive function, feeding behavior and cardiovascular regulation. NPY is co-stored with 
NE within peripheral sympathetic nerves that innervate vascular smooth muscle 
(Edvinsson, Emson, McCulloch, Tatemoto, & Uddman, 1983), heart (Gu, et al., 1983), 
gut (Gu, et al., 1983), liver (Taborsky, Beltramini, Brown, Veith, & Kowalyk, 1994), 
pancreas (Sundler, Moghimzadeh, Hakanson, Ekelund, & Emson, 1983), thyroid gland 
(Grunditz, Hakanson, Rerup, Sundler, & Uddman, 1984), respiratory tract (Sheppard, 
Polak, Allen, & Bloom, 1984), and eye (Terenghi, et al., 1983) tissues. NPY is also found 
in the adrenal glands (de Quidt & Emson, 1986; Majane, Alho, Kataoka, Lee, & Yang, 
1985) and is secreted by neural crest tumors such as neuroblastomas and 
pheochromocytomas (Grouzmann, Comoy, & Bohuon, 1989). 
Tatemoto et al., (Tatemoto, Carlquist, & Mutt, 1982) first isolated NPY from the 
porcine brain, and its name was attributed to the presence of a tyrosine at the N- and C- 
termini of the complete peptide. NPY is synthesized from the 97-amino acid precursor 
pre-pro-neuropeptide Y. Four posttranslational reactions are required to form the active 
NPY molecule (Higuchi, Costa, & Yang, 1988). Prohormone convertase 1/3 (PC1/3) 
break down proNPY at the paired basic site Lys38–Arg39, thereby releasing the 30 amino 
acid C-flanking peptide of NPY and NPY1-39 (Alfalah & Michel, 2004). NPY1-39 is further 
processed by a carboxypeptidase-like enzyme, leading to NPY1-37, which thereafter 
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becomes amidated at its C-terminal end by peptidyl-glycine-α-amidating 
monooxygenase, cleaving off another amino acid. The final biologically active fragment 
(NPY1-36) is referred to as NPY. 
1.3.1 NPY receptors 
NPY’s effects are mediated by the activation of a group of six Gi/Go-protein-
coupled receptors (Y1, Y2, Y3, Y4, Y5 and Y6 subtypes). The Y1, Y2, Y4, Y5 and Y6 
subtypes have been all cloned in rodents and humans (Bard, Walker, Branchek, & 
Weinshank, 1995; Eva, Keinanen, Monyer, Seeburg, & Sprengel, 1990; Weinberg, et al., 
1996), however only Y1, Y2, Y4 and Y5 appear to be functional in humans. NPY 
receptors have been grouped into subfamilies in which the Y1, Y4 and Y6 subtype make 
up the Y1 subfamily, and the Y2 and Y5 subtype each are in their own respective 
subfamily (Larhammar & Salaneck, 2004).  
Structurally, NPY receptors are seven-transmembrane heterotrimeric G-protein 
coupled receptors. Activation of G-protein coupled receptors lead to exchange of GDP 
for GTP by inactivated GDP-bound proteins on the Gα subunit, causing its dissociation 
from the Gβγ dimer. The active GTP-bound Gα subunit and the Gβγ complex will then 
modulate further downstream effects such as the inhibition of adenylate cyclase causing 
a decrease in cAMP. Zhu et al., confirmed this effect by blocking this response with 
pertussis toxin, supporting that NPY receptors are coupled to heterotrimeric inhibitory 
Gi/Go proteins (Zhu, Li, Toews, & Hexum, 1992). Furthermore, NPY stimulated increases 
in cAMP cause increases in secondary messengers such as cystolic calcium, which can 
increase the activity of other pathways such as the mitogen-activated protein kinase 
(MAPK) pathway (Nie & Selbie, 1998). 
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1.3.1.1 The Neuropeptide Y Y1-receptor 
The Y1 receptor (Y1R) was the first NPY receptor to be cloned, and initially 
discovered in the rat brain (Eva et al., 1990). Y1Rs are expressed throughout 
organs/tissues in the body, including the viscera, blood vessels and neural tissues (i.e. 
nerves and brain) (Korner, et al., 2004; Larhammar, et al., 1992; Matsuda, Brumovsky, 
Kopp, Pedrazzini, & Hokfelt, 2002; Mihara, Shigeri, & Fujimoto, 1990; Peaire, Krantis, & 
Staines, 1997). Y1R expression has also been reported in several types of endocrine 
tumors and epithelial malignancies, such as ovarian, prostate, breast and neural crest 
tumors (e.g., pheochromocytoma and paraganglioma) (Korner & Reubi, 2008; Korner, et 
al., 2004; Magni & Motta, 2001; Reubi, et al., 2001).  
Robust Y1R expression has been reported in several breast cancer tumors and 
cell lines. Reubi et al., reported expression of Y1R in 85% of breast tumor biopsy 
samples, whereas normal tissues showed little expression (Reubi, et al., 2001). Sherrif 
et al., probed several commonly used breast cancer cell lines and reported expression in 
MCF7, T47D, MDA MB-231, MDA MB-468, and HS578T cells (Sheriff, et al., 2010). Y1R 
expression has also been reported to be associated with estrogen levels in cancer cells, 
where estrogen was found to increase Y1 expression in MCF7 cells, which, when 
stimulated with Y1R agonists, caused a decrease in estrogen-stimulated cell proliferation 
(Amlal, Faroqui, Balasubramaniam, & Sheriff, 2006). 
The N-terminus is essential for NPY to activate Y1R, thus the complete NPY1-36 
molecule is necessary for NPY to bind to the Y1R. As the N-terminal part of the peptide 
is cleaved by membrane-bound peptidases, dipeptidyl peptidase IV (DPPIV or CD26) 
and aminopeptidase P (APP), the affinity of the peptide to the Y1R is diminished 
(Larhammar et al., 1992). As a result, N-terminally truncated NPY fragments such as 
NPY2-36, or NPY3-36 have affinity for Y2R and Y5R, and very little affinity for Y1Rs, 
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whereas alterations to the C-terminal residues have little effect on the affinity of the 
peptide for the Y1R. Therefore, the enzymatic activity of the aforementioned proteases 
may contribute to modulating the ratio in which Y1, Y2 and Y5 receptors are activated in 
tumors, and subsequently affect NPY mediated proliferation, migration and/or 
angiogenesis. 
1.3.1.2 The Neuropeptide Y Y2-receptor 
The Y2 receptor (Y2R) was first cloned from SMS-KAN cells and later from 
human brain and KAN-TX cells (Gerald, et al., 1995). Localized primarily presynaptically 
(Chen, DiMaggio, Han, & Westfall, 1997), Y2R’s have been found to regulate the release 
of NPY and other neurotransmitters (Wahlestedt, Edvinsson, Ekblad, & Hakanson, 1985; 
Zukowska-Grojec, Karwatowska-Prokopczuk, Fisher, & Ji, 1998). Expression of Y2Rs 
has been reported in the vasculature (Zukowska-Grojec, et al., 1998), the intestine 
(Rettenbacher & Reubi, 2001), brain (Stanic, et al., 2006) and breast tissue (Reubi, et 
al., 2001). Expression of the Y2R has been reported in neural endocrine tumors 
(Kitlinska, et al., 2005) and in breast cancer (Reubi, et al., 2001). However, the Y2R was 
found to predominate in normal breast tissue, switching to the Y1R subtype in neoplastic 
tissue, thus Y2R expressing tumors represented a small cohort of breast tumors. 
Y2R activation leads to an inhibition of adenylate cyclase and voltage dependent 
Ca2+ channels via Y2R coupled G-proteins. Cleaving of the N-terminus of NPY has little 
effect on the binding affinity to the Y2R. NPY fragments such as NPY2-36, NPY3-36 are of 
equal affinity to Y2Rs as the complete peptide, whereas, NPY13-36, PYY3-36, NPY22-36 will 
bind to Y2R with subnanomolar affinity (Beck-Sickinger & Jung, 1995). On presynaptic 
neurons, Y2R has been shown to be autoregulatory, as its activation can inhibit the 
release of neuronally derived NPY (Malmstrom, Lundberg, & Weitzberg, 2002). 
Activation of Y2Rs on neuroendocrine tumor cells has been reported to stimulate cell 
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proliferation (Kitlinska, et al., 2005; Movafagh, Hobson, Spiegel, Kleinman, & Zukowska, 
2006) and in endothelial cells shown to promote growth, migration and capillary tube 
formation (Movafagh, et al., 2006).  
1.3.1.3 The Neuropeptide Y5-Receptor 
The NPY Y5 receptor (Y5R) was first cloned in 1996 from mouse genomic DNA 
(Weinberg, et al., 1996). Sharing close homology with the Y1R, the Y5R consists of 60% 
of the same amino acids as the Y1R (Weinberg et al. 1996). Y5R expression has been 
reported throughout the body including gastrointestinal tract (Goumain, Voisin, Lorinet, & 
Laburthe, 1998), testis, pancreas, spleen, and skin (Statnick, et al., 1998). Centrally, the 
Y5R is expressed in the hypothalamus, cortex and brainstem (Grove, Campbell, 
Ffrench-Mullen, Cowley, & Smith, 2000). Growing evidence has demonstrated the 
prevalence of Y5Rs in several types of malignancies including colorectal, prostate, 
ovarian and breast (Patent no. US2011/0112102 A1). Recently, Y5R expression was 
reported in the MCF-7, T47D, MDA MB-231, MDA MB-468, HS578T and BT-549 cell 
lines (Sheriff, et al., 2010) (Table 1). 
 In the CNS, activation of the Y5R has been shown associated with appetite 
regulation and circadian cycle (Larhammar & Salaneck, 2004). Activation of Y5Rs on 
cardiomyocytes has been reported to promote cell growth/hypertrophy (Pellieux, et al., 
2000). The proliferative potential of Y5R activation has been reported in neuroblastomas 
(Kitlinska, et al., 2005) and more recently in BT-549 breast cancer cells (Sheriff 2010). 
Activation of the Y5R was shown to stimulate cell growth through increased mitogen-
activated protein kinase (MAPK) activity and concomitant with increased extracellular 
signal-regulated kinase (ERK 1/2) phosphorylation (Sheriff, et al., 2010). The role of the 
Y5R activation on breast cancer tumor progression has yet to be examined clinically or 
in an in vivo model.  
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Table 1.  NPY Y-receptor expression in human breast cancer cell lines. Data adapted 
from Sheriff et. al (Sheriff, et al., 2010). 
Cell Line Y1R Y2R Y5R 
MCF-7 + - + 
T47D + - + 
MDA MB-231 + - + 
MDA MB-468 + - + 
HS578T + - + 
BT-549 - - + 
 
1.3.2 NPY Stimulated Cell Proliferation 
NPY has been shown to stimulate proliferation in different vascular tissues 
including endothelial and vascular smooth muscle cells (Shigeri & Fujimoto, 1993; 
Zukowska-Grojec, et al., 1998), as well as cardiomyocytes (Pellieux, et al., 2000). NPY’s 
mitogenic properties are dependent on the presence of the Y1R, Y2R and Y5R. 
Activation of one or more of these receptors has been shown to increase DNA synthesis 
and cell proliferation in a dose-dependent manner (Shigeri & Fujimoto, 1993). NPY 
stimulated proliferation occurs through an increase in mitogen-activated protein kinase 
(MAPK) activity, leading to increased extracellular signal-regulated kinase (ERK 1/2) 
phosphorylation (Pellieux, et al., 2000; Sheriff, et al., 2010; Zukowska-Grojec, et al., 
1998). This response has been observed in prostate cancer cells (Ruscica, et al., 2006), 
neuroblastoma cells and recently in breast cancer cells (Sheriff, et al., 2010). 
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1.3.3 NPY Stimulated Chemotaxis 
Chemotaxis is defined as the movement of an organism or cell along a chemical 
(chemo-attractant) concentration gradient either towards or away from the chemical 
stimulus. Chemotactic potential is commonly examined with the use of a Boyden 
chamber assay. Originally developed to analyze leukocyte chemotaxis, a Boyden 
chamber is composed of two medium-filled compartments separated by a microporous 
membrane. Cells placed in the top chamber will migrate through micropores toward a 
chemoattractant, which fills the bottom chamber. NPY has been shown to be a 
chemoattractant to monocytes, macrophages, and endothelial cells (Straub, et al., 
2000). Limited studies have demonstrated NPY potential to increase cell migration in 
different types of cancer cells (Sheriff, et al., 2010) such as breast cancer cells. Drell et 
al., (Drell, et al., 2003) reported that sympathetic neurotransmitters met-enkephalin, 
substance P, bombesin, dopamine, and norepinephrine had a stimulatory effect on the 
migration of the breast cancer cells, but the effects of NPY were not examined. 
1.3.4 NPY Stimulated Angiogenesis 
Briefly, angiogenesis is the process of new blood vessel formation from pre-
existing vessels. This process occurs minimally under homeostatic conditions, and it is 
integral to responses such as wound healing (Knighton, Silver, & Hunt, 1981). During 
pathological conditions such as cancer, angiogenic activity also increases to supply a 
tumor with new vasculature. In vitro assays have demonstrated NPY’s angiogenic 
potential, and, under physiological concentrations, NPY stimulates adhesion, migration, 
proliferation and capillary tube formation in human endothelial cells (Movafagh, et al., 
2006; Zukowska-Grojec, et al., 1998). These responses initially thought to be meditated 
solely by the Y2R, were later reported to occur bimodally via Y1R, Y2R or Y5R activation 
(Movafagh, et al., 2006). In vivo studies have further supported NPY’s angiogenic 
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actions through Y2R activation, as Y2R knockdown mice exhibit compromised wound 
healing (Ekstrand, et al., 2003; Lee, Grant, Movafagh, & Zukowska, 2003). Moreover, 
hypoxia-induced retinal angiogenesis is absent in neonatal Y2 deficient mice (Koulu, et 
al., 2004). In the context of breast cancer progression, NPY is postulated to be an 
angiogenic factor contributing to new vessel formation during tumor development. 
Interestingly, neurotransmitters such as NE can function in a paracrine manner, 
stimulating the release of pro-angiogenic factors such as vascular endothelial growth 
factor (VEGF) from cancer cells (Madden, Szpunar, & Brown, 2011). Whether NPY can 
function through a similar mechanism in breast cancer has yet to be examined.  
1.4 Rationale 
Investigating the contribution of NPY to breast cancer progression is reasonable 
when the following points are considered: 1) sympathetic nerves arising from the lateral 
and anterior cutaneous branches of the second to sixth intercostal nerves richly 
innervate the human breast. These nerves provide a constant supply of NPY to the 
mammary gland, smooth muscle of the areola, skin and breast blood vessels, 2) women 
with family histories of breast cancer have elevated sympathetic neurotransmitters 
release in response to daily stressors (James, et al., 2004), and 3) NPY receptors are 
expressed in several breast cancer cells (Korner & Reubi, 2007). Given the few 
investigations examining the role of NPY in breast cancer, the impetus for this thesis 
was to characterize the functional impact of NPY in breast cancer and develop an in vivo 
breast cancer model in which the effects of NPY could be studied in an immuno-intact 
model.  
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1.5 Overall Objective 
The overall objective of this thesis was to elucidate the impact of the sympathetic 
NPY system on breast cancer development and to develop an in vivo model in which it 
could be functionally studied. 
1.5.1 Specific Objectives 
Manuscript 1: Chapter 2 
Test for the presence of NPY receptors in the 4T1 model, and determine whether NPY 
elicits proliferative and chemotactic effects on 4T1 cells.  
Manuscript 2: Chapter 3 
Determine the mechanisms of NPY-stimulated angiogenesis in human and murine 
breast cancer models. 
Manuscript 3: Chapter 4  
Develop an in vivo model of breast cancer to allow for the examination of the 
components of the sympathetic NPY system. 
To address these objectives, experiments conducted within this thesis utilized 
several NPY receptor specific agonists and antagonists, summarized in Table 2. 
Table 2. NPY receptor agonists and antagonists.  
 
Y1R Y2R Y5R 
Agonists NPY 
[Leu31,Pro34]-NPY 
NPY 
    PYY3-36 
NPY 
[cPP1-7,NPY19-
23,Ala31,Aib32,Gln34]–
hPP 
Antagonists BIBP3226 BII0246 L-152,802 
TAC557 
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1.6 Thesis Hypotheses 
1.6.1 Overall Working Hypothesis 
Overall we hypothesize that the NPY system is involved in breast cancer tumor 
formation.  
1.6.2 Specific Hypotheses 
1) We hypothesized that 4T1 cells and tumors express NPY receptors. (Tested in 
Chapter 2) 
2) We hypothesized that NPY would stimulate proliferation of 4T1 cells and 
increase tumor growth. (Tested in Chapter 2 and 4) 
3) We hypothesized that NPY would cause an increase in chemotaxis. (Tested in 
Chapter 2) 
4) We hypothesized that NPY would stimulate an increase in expression and 
secretion of VEGF from breast cancer cells, promoting in vitro angiogenesis. 
(Tested in Chapter 3) 
5) We hypothesized that sympathetic dennervation of the mammary gland would 
attenuate tumor growth and vascularity. (Tested in Chapter 4) 
6) We hypothesized that treating tumor-bearing mice with the Y5R antagonist 
TAC557 would attenuate tumor growth. (Tested in Chapter 4) 
 
 
 
 Figure 1.1 Thesis Road Map
the sympathetic NPY system on the progression of breast cancer
conducted to determine if NPY receptor (YR) activation would stimulate proliferation and 
migration of 4T1 cells. Additionally, the effects of YR activation on VEGF expression and 
secretion were examined. 
model in which the components of the NPY system (i.e., nerves, ligand and receptors) 
could be functionally studied.
  
.  In the current thesis we sought to elucidate the impact of 
In vitro findings supported the development of the 4T1 tumor 
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Chapter 2  
2 Neuropeptide Y stimulates proliferation and migration in 
the 4T1 breast cancer cell line 
Content from this chapter has been in part adapted from “Neuropeptide Y 
stimulates proliferation and migration in the 4T1 breast cancer cell line”., by P.J 
Medeiros, B.K Al-Khazraji, N.M Novielli, L.M Postovit, A.F Chambers and D.N Jackson. 
International Journal of Cancer 2011 Aug 5. doi: 10.1002/ijc.26350. 
2.1 Introduction 
Recent studies have demonstrated that stress is correlated with increased breast 
cancer risk. Chronic stress leads to elevated sympathetic neurotransmitter release (NE 
and NPY), which is associated with immunosuppression, and has been positively 
correlated with increased incidences of infection and cancer (Antoni, et al., 2006; 
Elenkov, Wilder, Chrousos, & Vizi, 2000; Marsland, Bachen, Cohen, Rabin, & Manuck, 
2002; McEwen & Stellar, 1993; Tilan & Kitlinska, 2010). Sympathetic nerves arising from 
the lateral and anterior cutaneous branches of the second to sixth intercostal nerves 
abundantly innervate the human breast, thereby providing a constant supply of 
sympathetic ligands to the breast microenvironment. Interestingly, women with family 
histories of breast cancer are reported to have greater sympathetic neurotransmitter 
release under normal conditions (James, Berge-Landry Hv, Valdimarsdottir, 
Montgomery, & Bovbjerg, 2004). As such, the pathological contributions of these 
neurotransmitters to breast cancer development and progression have been a growing 
area of investigation. 
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In mammalian systems, NPY is the most abundantly expressed peptide of the 
pancreatic polypeptide family, exhibiting pleiotropic actions throughout the body. The 36-
amino acid peptide is most widely expressed in the central and peripheral nervous 
systems, playing major roles in cognitive function, feeding behavior and cardiovascular 
regulation. NPY activates a group of six NPY G protein-coupled receptors (Y1R-Y6R) of 
which the Y1R, Y2R and Y5R are most abundantly expressed in humans, and have 
been most extensively studied (Michel, et al., 1998). In addition to regulating several 
physiological functions, NPY has been shown to promote proliferation, vascularization 
and stimulate migration in several cell types and tissues (Kuo, Abe, & Zukowska, 2007; 
Ruscica, Dozio, Motta, & Magni, 2007; Zukowska-Grojec, Karwatowska-Prokopczuk, 
Rose, et al., 1998; Zukowska-Grojec, et al., 1993). 
NPY Y1R, Y2R and Y5R expression has been reported in several breast cancer 
cell lines (Reubi, Gugger, Waser, & Schaer, 2001; Sheriff, et al., 2010). In human 
primary breast carcinomas, 85% exhibited Y1R expression, while only 24% expressed 
the Y2R subtype (Reubi, et al., 2001). Recently, Y5R expression was found in the MCF-
7, T47D, MDA MB-231, MDA MB-468, HS578T and BT-549 cell lines (Sheriff, et al., 
2010). Activation of Y5R in BT-549 cells was shown to stimulate cell growth through 
increased mitogen-activated protein kinase (MAPK) activity and concomitant with 
increased extracellular signal-regulated kinase (ERK 1/2) phosphorylation (Sheriff, et al., 
2010). In contrast, Y1R activation in MCF-7 cells has been reported to inhibit estrogen-
induced proliferation (Amlal, Faroqui, Balasubramaniam, & Sheriff, 2006). The Y2R has 
also been shown to increase cellular proliferation, however current studies have been 
limited to neuroendocrine tumors, which highly express the receptor (Kitlinska, et al., 
2005; Korner & Reubi, 2008).  
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The contribution of NPY to the development of metastasis has been a question of 
increasing importance. Neuropeptides have been reported to exhibit chemotactic 
potency and stimulate migratory activity of immune (Straub, et al., 2000), endothelial 
(Movafagh, Hobson, Spiegel, Kleinman, & Zukowska, 2006) and breast cancer cells 
(Drell, et al., 2003; Sheriff, et al., 2010). Substance P and bombesin have been 
observed to increase migratory activity in MDA MB-468 cells (Drell, et al., 2003) and 
more recently NPY stimulation was reported to increase the migration of MDA MB-231 
cells through Y5R activation (Sheriff, et al., 2010). 
The 4T1 murine mammary cancer cell line is a well-established model of breast 
cancer. It has been used extensively to study anti-metastatic and anti-angiogenic 
therapies (Lin, et al., 1998; Prewett, et al., 1999), however the effects of NPY on this 
breast cancer model have yet to be examined. Therefore, in the current study, using 
qPCR, Western blot and immunohistochemical analyses we examined the expression of 
Y1R, Y2R and Y5R in 4T1 cells in vitro and in orthotopic tumors. Positive expression for 
each of the three receptors led our group to test whether NPY would stimulate 
proliferation and/or migration in this model. Using NPY receptor antagonists, we provide 
evidence of Y5R mediated proliferation and Y2R and Y5R mediated chemoattraction to 
NPY treatment. These data complement and parallel recent findings in human cell lines, 
and highlight the 4T1 cell line as a breast cancer model in which the effects of NPY can 
be studied in an immuno-intact in vivo model.   
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2.2 Materials and Methods 
2.2.1 Reagents and Drugs 
Fetal bovine serum (FBS), culture media, Hanks Balanced salt solution (HBSS) 
and trypsin were purchased from Invitrogen (Invitrogen Canada Inc., Burlington, ON, 
Canada). RNA isolation was performed using PureZol© (Aurum Total RNA Mini Kit, Bio-
Rad Laboratories, Hercules, CA, USA) and cDNA was synthesized using a RT2 First-
Strand cDNA synthesis kit (QIAGEN Inc, Mississauga ON, Canada). Primer pairs 
corresponding to target genes for mouse NPY Y1R (Cat no. PPM042483E), NPY Y2R 
(Cat no. PPM04278A), NPY Y5R (Cat no. PPM04629A) and GAPDH (Cat no. 
PPM02946E) were purchased from QIAGEN (Mississauga, ON, Canada). 
Cell lysis buffer (M-PER Mammalian Protein Extraction Reagent), protease and 
phosphatase inhibitors (Halt Phosphatase Inhibitor Cocktail) were purchased from 
Pierce (Rockford, IL, USA). For Western blot analysis we used primary antibodies 
specific to mouse NPY Y1R, Y2R, Y5R (Cat no. NPY1R11-A, NPY2R11-A, NPY5R11-A, 
Alpha Diagnostic International, San Antonio, TX, USA), phospho-ERK 1/2 and total ERK 
1/2 (Cell Signaling Technology, Inc.). For secondary incubation we used antibody 
conjugated to horseradish peroxidase (goat anti-rabbit IgG, Cat no. A0545, Sigma 
Aldrich, St Louis, MO, USA). NPY (non-specific YR agonist), Peptide YY (3-36) 
(Y2R/Y5R agonist), [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPancreatic Polypeptide 
(hPP; Y5R agonist), BIBP3226 (Y1R antagonist), BIIE0246 (Y2R antagonist), and L-
152,802 (L-152; Y5R antagonist) were from Tocris (Minneapolis, MN, USA). Cell 
proliferation was measured by tetrazolium-based assay from Promega (CellTiter 96® 
AQueous One Solution, Madison, WI, USA).  
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2.2.2 Cell Culture 
4T1 cells, a gift from Dr. Fred Miller (Wayne State University, Michigan, USA), 
were cultivated in high glucose Delbecco’s Minimal Essential Medium (DMEM) 
supplemented with 10% sterile FBS. Cells were incubated at 37ºC and 5% carbon 
dioxide. At approximately 80% confluency, cells were washed with HBSS and passaged 
using 0.25% trypsin-EDTA treatment for dissociation.  
2.2.3 Quantitative RT-PCR 
 Total RNA was isolated from ~5 × 106 4T1 cells using PureZol© following 
manufacturer’s protocols. Five micrograms of RNA was reverse-transcribed in a 25µl 
reaction. Primer pairs were used to amplify the target genes for mouse NPY Y1R, NPY 
Y2R, NPY Y5R and GAPDH. 
Relative quantification of target mRNA was performed using SYBR® green 
quantitative RT-PCR detection (CFX 96 real-time PCR detection system, Bio-Rad, 
Hercules, CA, USA). Twenty-five microliter reactions were conducted with equal 
amounts of cDNA templates from each sample (triplicate) according to the 
manufacturer’s protocol. The protocol was: 95°C for 10 minutes, 40 cycles at 95°C for 15 
seconds, 60°C for 60 seconds. At the end of the protocol, a stepwise increase in 
temperature from 65°C to 95°C was performed and dissociation curves were constructed 
to ensure purity of PCR products. Data were analyzed with CFX manager software (Bio-
Rad, Hercules, CA, USA). Target gene expression was quantified by measuring 
threshold cycle. Experiments were repeated three times. 
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2.2.4 Orthotopic Tumor Model 
Seven female BALB/c mice, purchased from Charles River Laboratories (Saint-
Constant, QC, Canada) at 7-9 weeks of age, were used in the current study. Animals 
were housed in the animal care facility at The University of Western Ontario. They were 
maintained on Harlan 2018, Teklad Global 18% Protein Rodent Diet and water ad libitum 
and kept on a 12 hr light/dark cycle. All experimental procedures were carried out with 
the approval of the Council on Animal Care at The University of Western Ontario. 
After three passages, 4T1 cells were prepared for injection. Cells were washed 
and resuspended in sterile HBSS. The solution was filtered with a 40 µm cell strainer 
and cell viability was assessed by trypan blue staining and counting with a 
hemocytometer. The cell suspension was diluted to 103 cells/µl for injection. 
 Animals were anesthetized with isofluorine/oxygen gas mask (2-3% isofluorine, 
1 L/min) and hair was removed from the lower abdominal region using commercial hair 
remover (Nair®). A sagittal cut (~1 cm) was made at the lower abdomen and skin was 
separated from the underlying muscle, to expose the underlying mammary fat pad. One 
hundred microliters (105 cells) of cell suspension was carefully injected into the right 
inguinal mammary fat pad. Wound clips were then applied to close the skin incision. 
Animals were returned to their cage for recovery and wound clips were removed 7 days 
later. Animals were then housed in cages without disturbance for 29 days. Twenty-nine 
days post-injection, all mice were sacrificed after induction of anesthesia using Ketamine 
(100 mg/kg) and Xylazine (25 mg/kg) followed by cervical dislocation. Mammary tumors 
were removed from each animal, sectioned in half, one half flash frozen in liquid nitrogen 
and the other fixed in 4% paraformaldehyde.  
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2.2.5 Western Blot Analysis 
 Cultured cells from a 25 cm2 flask were washed twice in ice cold HBSS and then 
lysed in 500 µl lysis buffer containing protease  (104 mM AEBSF, 80 µM aprotinin, 2.1 
mM leupeptin, 3.6 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64) and phosphatase 
(Halt Phosphatase Inhibitor Cocktail) inhibitors. Cells were scraped and then lysed by 
sonication. One hundred milligrams of tumor tissue was immersed in ice-cold lysis buffer  
(50 mM Tris, pH 7.5, 150 mM sodium chloride, 5 mM ethylene glycol tetraacetic acid, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and 1% Triton-X 100) and 
mechanically homogenized. Cell and tissue lysates were centrifuged for 15 minutes at 
14,000 rpm at 4°C. Supernatant was collected and stored at -80°C until protein 
concentration was determined.  
A Bradford assay (Bradford, 1976) was performed to determine total protein 
concentration of samples.  Thirty-five micrograms of protein from each sample and a 
positive control (brain lysate) were loaded on a 4% to 12% gradient gel and separated 
by SDS-PAGE. After electrophoresis, proteins were transferred at a constant voltage to 
polyvinylidene fluoride membranes. Membranes were blocked for 1hr in 5% milk in Tris-
Buffered Saline + Tween20 (0.5%) (TTBS) at 4°C. Membranes were then incubated in 
primary antibody specific to mouse NPY Y1R, Y2R, and Y5R in 5% milk TTBS at a 
concentration of 1:1000 at 4°C overnight. Membranes were washed in TTBS then 
incubated in secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit 
IgG, 1:2000) in 2% milk in TTBS for 1 hr.  Membranes were washed three times and 
bands were detected using an Immun-Star WesternC© chemiluminescent kit (Bio-Rad, 
Hercules, CA, USA) and imaged with the ChemiDoc XRS System (Bio-Rad, Hercules, 
CA, USA). Membranes were washed, stained for total protein using Amido black, and 
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imaged using the ChemiDoc XRS. Densitometric band analysis was performed with 
Quantity One 1-D Analysis Software (Bio-Rad, Hercules, CA, USA).   
2.2.6 Cell Proliferation Experiments 
Twenty five hundred cells were seeded per well of 96-well plates and incubated 
for 24 hrs in DMEM supplemented with 10% FBS. After 24 hrs media was replaced with 
experimental medium (DMEM + 2% FBS) containing 10-11 to 10-6 M NPY (Tocris, 
Minneapolis, MN, USA). The proliferative effect of NPY was tested using an MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
based assay (CellTiter 96® AQueous One Solution, Madison, WI, USA). Proliferation was 
measured after 24 hr, 48 hr and 72 hr of NPY treatment. These experiments were 
conducted in triplicate (per concentration) and repeated at least four times. These 
experiments were repeated with Peptide YY (3-36) and Y5R specific agonist: [cPP1-
7,NPY19-23,Ala31,Aib32,Gln34] - hPancreatic Polypeptide. 
In order to elucidate the contribution of each respective receptor to NPY-
stimulated proliferation, receptor antagonist experiments were conducted. Twenty-four 
hrs after cells were seeded, experimental media containing NPY (10-8 M, peak effective 
dose) and one of three antagonists (BIBP3226, BIIE0246 or L-152) were added. For 
each drug, increasing doses (10-9 M to 10-4 M) were added to wells and cell proliferation 
was measured at 24, 48 and 72 hrs. Media was replaced every 24 hrs 
(triplicate/concentration, n=4 per experiment). These experiments were repeated in the 
absence of NPY to ensure antagonist treatment had no toxic or anti-proliferative effects.  
Drugs were reconstituted in HBSS and all treatments were compared to control cells that 
were incubated in experimental media containing an equal volume of HBSS as peptide, 
agonist or antagonist treated cells. 
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2.2.7 NPY-Stimulated ERK1/2 phosphorylation 
NPY receptor activation has been shown to stimulate MAPK activity, leading to 
increased ERK 1/2 phosphorylation (pERK) and cell proliferation. To confirm that our 
NPY treatment stimulated MAPK activity in the 4T1 cell line, a time-point experiment was 
conducted to examine the effect of NPY treatment (10-8 M) on pERK 1/2. 4T1 cells (5 x 
104) were seeded in 60 mm diameter tissue culture dishes in culture media and left to 
incubate for 24hrs. Cells were then growth-arrested for 24hrs with experimental DMEM 
plus 0.1% BSA. Individual dishes were then treated with experimental media containing 
NPY (10-8 M) for 2, 5, 15, 30 and 60 minutes (n=4/time point). After which, cells were 
washed three times in ice cold HBSS, 100µl of lysis buffer was added to the dish and 
cells were scraped. Lysates were centrifuged for 15 minutes at 14000 rpm at 4°C. 
Supernatant was collected and stored at 4°C until protein concentration was determined 
on the following day. Samples were then analyzed by Western blot for pERK and total 
ERK expression using antibodies specific to each respective protein rabbit anti-mouse 
phospho-p44/42 MAPK (Erk1/2) 1:1000 and rabbit anti-mouse p44/42 MAPK (Erk 1/2) 
1:1000. Blots were repeated four times and densitometric analysis was conducted for 
each blot. NPY stimulated phosphorylation of ERK 1/2 was quantified as the level of 
pERK 1/2 normalized to total ERK 1/2. 
2.2.8 Live/Dead® Viability Assay 
 To assess the effects of experimental drug treatments on cell viability we used a 
two-color fluorescence cell viability assay (Live/Dead® Viability Kit, Molecular Probes, 
Eugene, OR, USA). We repeated experimental conditions from proliferation experiments 
(96-well format), cells were then treated with calcein acetoxymethyl ester (1µM) and 
ethidium homodimer (2µM) according to manufacturer’s protocol. Fluorescence was 
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measured on a microplate spectrofluorimeter (calcein acetoxymethyl ester excitation 
filter: 485nm; emission: 530nm, ethidium homodimer excitation filter: 530nm; emission: 
645nm). Data were expressed as a percent change of control. 
2.2.9 Chemotaxis Assays 
Cell chemotaxis was assessed using a modified Boyden chamber apparatus with 
a 12-well plate and cell culture inserts with polyethylene terephthalate (PET) membranes 
and 8µm pores (BD Biosciences). The upper surfaces of the insert membranes were 
coated with 0.1% gelatin and left overnight. The following day, the gelatin surface was 
rehydrated with serum-free media for 1 hr and 4T1 cells (1.5 × 105) were plated in the 
upper chamber in serum-free media. To examine the chemotactic potential of NPY, cells 
were exposed to a range of NPY-treated media (10-11-10-6 M) placed in the bottom 
chamber. To examine receptor-specific effects of NPY on chemotaxis, cells were 
incubated separately in Y1R, Y2R or Y5R antagonists for 30 minutes. After incubation, 
cells were added to the upper chamber in wells containing a range of Y-receptor 
antagonist treated serum free media (10-9-10-4 M), while NPY treated media (10-8 M, 
previously determined peak effective dose) was added to the bottom chamber. All 
treatments were carried out in triplicate and experiments were repeated at least three 
times.  After 6 hrs of incubation, the gelatin and cells remaining on the top of the 
membrane were removed using cotton swabs. Migrated cells (on the bottom of the 
membrane) were fixed and stained with 0.5% Crystal violet in methanol. The 
membranes were carefully removed, mounted on slides, and imaged using a light 
microscope at 10x magnification (Zeiss Axioskop, Nikon DXM1200 camera). From the 
images, the total number of migrated cells were manually counted and recorded. In all 
cases, experimental conditions for slides were blinded during counting. 
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2.2.10 Statistical Analyses 
Statistical analysis was performed using GraphPad software, (Version 4.0a, 
GraphPad Software Inc) and data are presented as mean ± SEM. Non-linear regression 
analysis was performed on proliferation and chemotaxis experiments to test if the effects 
of NPY were concentration-dependent and to determine the peak effective NPY dose to 
be used in antagonist experiments. Statistical differences between treatments were 
evaluated by one-way repeated measure ANOVA, followed by Tukey’s HSD test. The 
level of statistical probability was set at P<0.05. 
2.3 Results 
2.3.1 NPY Receptor Expression in the 4T1 Cell Line 
 Quantitative real-time PCR revealed expression of mRNA for Y1R, Y2R and Y5R 
in the 4T1 cell line (Figure 2.1 A). Additionally, receptor protein expression was 
confirmed by Western blot analysis (Figure 2.1 B). Immunocytochemical staining 
revealed positive Y1R, Y2R and Y5R expression in 4T1 cells (Figure 2.1 C). 
Membranous and cytoplasmic staining was observed, with the Y5R exhibiting the most 
prevalent expression. Y1R, Y2R and Y5R expression was also observed in histological 
sections (Figure 2.1 D). Receptor expression was observed on tumor cell membranes 
and was detected on blood vessel endothelium. 
  
 Figure 2.1. Y1, Y2 and Y5 receptor expression. 
expression in the 4T1 cell line (A. CT values). 
lysates provided evidence of Y1R, Y2R and Y5R expression in this model (brain as a 
postive control) (B.). Immunohistochemical analysis (DAB and hematoxylin) of cells (C.) 
and tumor sections (D.) confirmed NPY receptor expression.
cytoplasmic and membranous staining of receptors; the Y5R subtype exhibiting the 
greatest expression. In tumors, staining was observed on tumor cell membranes and 
was also detected on blood vessel endothelium (C. scale bar = 10 µm; D. sc
µm). 
 
qPCR indicated NPY receptor mRNA 
Western blot analysis of
 4T1 cells exhibited positive 
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2.3.2 Cell Proliferation Experiments 
NPY treatment stimulated a concentration-dependent (r2=0.94) increase in 
proliferation measured at 24 hrs (Figure 2.2 A), 48 hrs and 72 hrs (Appendix). When 
compared to control cells, a proliferative effect of NPY was observed at 10-10 M and was 
maximal at 10-8 M (P<0.05). Similarly, treatment with the Y5R specific agonist, [cPP1-
7
,NPY19-23,Ala31,Aib32,Gln34]–hPP also stimulated a concentration-dependent increase in 
proliferation (r2=0.97) after 24 hrs, at a concentration of 10-10 M, plateauing at a 
concentration of 10-9 M (P<0.05, Figure 2.2 B). 
2.3.3 Effect of NPY on Phosphorylation of ERK 1/2.  
After 24 hrs of serum-free incubation low basal levels of pERK 1/2 were 
observed (0 minute: Figure 2). NPY treatment significantly increased pERK 1/2 levels 
after 2 minute and 5 minute incubations (Figure 2.2 A, P<0.05), and by 15 minutes pERK 
1/2 levels returned to basal levels. Y5R agonist, [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPP 
treatment caused an increase in pERK 1/2 levels after 5 minutes (P<0.05, Figure 2.2 B). 
Increased pERK 1/2 activity could not be blocked by BIBP3226 and BIIE0246 at 
concentrations from 10-8 to 10-4 M (Figure 2.3. A & B: 10-4 M and 10-5 M respectively). 
NPY and Y5 agonist stimulated increased pERK 1/2 activity and was blocked by L-
152,804 (10-4 M)  (P< 0.05, Figure 2.3 C & D).  
  
 Figure 2.2. Effect of peptidergic treatment on proliferation and ERK1/2 phosphorylation of 
4T1 cells. Proliferation (MTS
in cells treated with media containing NPY
hPP (10-9M) (B.). A concentration
of peptide treatment (r2=0.94 and 0.97 respectively). Peptide treatment significantly increased 
proliferation compared to cells in experimental medium (Ctrl; DMEM + 2% FBS, n=4, P<0.05). 
Western blot analysis was used to examine ERK 1/2 phosphorylation in
(A.) and [cPP1-7,NPY19-23,Ala
minutes and 1 hr. Peptide treatment stimulated an increase in pERK 1/2 at 2 minutes (NPY) and 
5 minutes (NPY and [cPP
returned to non-treated levels (0 minutes). Densitometric data are presented as pERK 1/2 
normalized to total ERK 1/2. Data are presented as mean ± SEM  (n=4, * represents differences 
from Ctrl. P<0.05, one-way A
 assay) and ERK 1/2 phosphorylation (Western blot) were measured 
 (10-8M) (A.) and [cPP1-7,NPY19-23,
-dependent increase in proliferation was observed after 24 hrs
 cells treated with NPY 
31
,Aib32,Gln34]–hPP (B.) for 2 minutes, 5 minutes, 15 minutes, 30 
1-7
,NPY19-23,Ala31,Aib32,Gln34]–hPP) after which pERK 1/2 levels 
NOVA). 
36 
 
Ala31,Aib32,Gln34]–
 
 37 
 
38 
 
Figure 2.3. Effect of NPY receptor activation and blockade (Y1R, Y2R and Y5R) on 
cell proliferation and ERK 1/2 phosphorylation. Cells were treated with NPY (10-8 M) 
and one of three antagonists (A. Y1R: BIBP3226; B. Y2R: BIIE0246; C. Y5R: L-152,804; 
10-8-10-4 M). NPY-stimulated proliferation was not blocked by Y1R antagonism or Y2 
antagonism (Y1R: 10-4 M Y2R: 10-5 M). Y5R antagonism (10-4 M) abolished the 
proliferative effects of NPY (*P<0.05). Y5R agonist treatment (D., [cPP1-7,NPY19-
23
,Ala31,Aib32,Gln34]–hPP 10-9 M) caused an increase in proliferation which was blocked 
by L-152,804. ERK 1/2 phosphorylation increased when cells were treated with NPY and 
[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP; this effect was blocked by L-152,804 treatment. 
Panels depict peak antagonist concentrations used, all experiments were repeated four 
times (n=4), data are presented as mean ± SEM  (* Represent differences from Ctrl.  
P<0.05, one-way repeated measures ANOVA). 
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2.3.4 Effect of NPY receptor blockade (Y1, Y2 and Y5) on cell 
proliferation.  
The independent contributions of Y1R, Y2R and Y5R activation on proliferation 
were tested by receptor-specific antagonist supplementation. Cells were incubated with 
media containing NPY (10-8 M, peak proliferative concentration) and BIBP3226, 
BIIE0246 or L-152,804 (10-8 to 10-4 M). At all time points, NPY treatment led to increased 
proliferation compared to vehicle containing media (Control) (P<0.05, Figure 2.3). Of the 
three antagonists tested, only the Y5R antagonist (L-152,804) inhibited the proliferative 
effect of NPY (P<0.05, Figure 2.3 C). Compared to control, there was no change in NPY 
stimulated proliferation in cells exposed to Y1R antagonism (BIBP3226) (Figure 2.3 A: 
10-4 M) or Y2R antagonism (BIIE0246) (Figure 2.3 B: 10-5 M). Y5R agonist treatment (10-
9 M) also caused an increase in proliferation which was blocked by L-152,804 (Figure 2.3 
D: 10-4 M). Control experiments were conducted with each antagonist in the absence of 
NPY, and we observed BIIE0246 to be toxic at 10-4 M, while no toxic or proliferative 
effects were observed from L-152,804 or BIBP3226 treatment at concentrations (10-8 to 
10-4 M) used in blockade experiments (Figure 2.4). 
2.3.5 Cell Viability 
NPY treatment (10-8 M) led to an increase in the percent of live cells compared to 
control and had no effect on cell death (P<0.05, Figure 2.4). Treatment with [cPP1-
7
,NPY19-23,Ala31,Aib32,Gln34]–hPP (10-9 M) led to a similar increase in the percent of live 
cells. Compared to control cells, independent treatment with the receptor antagonists 
BIBP3226 (10-4 M), BIIE0246 (10-5 M) or  L-152,804 (10-4 M) had no effect on cell viability 
or cell death. 
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 Figure 2.4 Effect of peptide and antagonist treatments on cell viability.
experimental drug treatments (from proliferation experiments) on cell viability was 
assessed with a Live/Dead
8M) , [cPP1-7,NPY19-23,Ala
BIIE0246 (10-5 M), or L-152,804 (10
(Dead, emission: 645 nm) fluorescence was measured and compared to control cells 
(DMEM + 2% FBS). NPY and Y5R agonist treatment led to an increase in the percent of 
live cells and there was no effect of these drug treatments on cell death. Data are 
expressed as a percent change of control (
from Ctrl. P<0.05, one-way ANOVA).
®
 viability assay. Cells were treated for 24 hrs with NPY (10
31
,Aib32,Gln34]–hPP (Y5R agonist; 10-9 M), BIBP3226 (10
-4 M). Calcein (Live, emission: 530 nm) and ethidium 
mean ± SEM; n=6; * represents differences 
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 The effect of 
-
-4 M), 
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2.3.6 NPY- Stimulated Chemotaxis 
NPY induced a concentration-dependent increase in chemotaxis with a peak 
concentration of 10-8 M (Figure 2.5 A). At NPY concentrations of 10-9 to 10-6 M, 
chemotaxis was significantly augmented compared to untreated cells (Ctrl). Similarly, 
PYY3-36 (Y2R/Y5R agonist) and Y5R agonist treatment stimulated a concentration-
dependent increase in chemotaxis (Figure 2.5 B & C). Treatment of cells with Y1R 
antagonist (BIBP3226) had no effect on NPY-stimulated chemotaxis (Figure 2.6 A), 
whereas Y2R blockade (BIIE0246) attenuated NPY-mediated increases in cell 
chemotaxis at 10-6 M (P<0.05, Figure 2.6 B). In addition, NPY-mediated increase in cell 
chemotaxis was attenuated when cells were treated with Y5R antagonist (L-152,804) at 
all concentrations tested (10-8-10-4 M) (P<0.05, Figure 2.6 C). 
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Figure 2.5 Peptidergic stimulated chemotaxis of 4T1 cells. Cell chemotaxis was 
assessed using a modified Boyden chamber. Cells were seeded (2 × 104 cells) in serum-
free media in the top chamber and were exposed to A. NPY, B. PYY3-36 (Y2R/Y5R 
agonist), and C. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP (Y5R agonist) (10-11-10-6 M)  in 
DMEM in the lower chamber. After 24 hrs migrated cells were fixed, stained with DAPI 
and imaged. Cells were counted by Matlab® based software. Peptide treatment elicited a 
concentration-dependent increase in chemotaxis compared to control cells. Data are 
presented as mean ± SEM,  (n=4, * represent differences from Ctrl;  P<0.05, one-way 
ANOVA). 
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Figure 2.6 Effect of NPY receptor activation and blockade (Y1R, Y2R and Y5R) on 
chemotaxis. NPY receptor antagonists A. Y1R: BIBP3226; B. Y2R: BIIE0246; and 
C.Y5R: L-152,804) were added to the upper chamber (10-8-10-4 M) and NPY treated 
media (10-8 M) was added to the bottom chamber. Treatment of cells with BIBP3226 had 
no effect on NPY-stimulated chemotaxis, while BIIE0246 and L-152,804 inhibited the 
chemotactic effects of NPY. The data are presented as the mean ± SEM,  (n=4, * 
represent differences from Ctrl. P<0.05, one-way ANOVA). 
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2.4 Discussion 
A neuroendocrine influence on breast cancer progression has been a postulate 
of recent interest. In the current, study we have presented data supporting this postulate 
in the 4T1 breast cancer model. We report for the first time the expression of the Y1R, 
Y2R and Y5R in the 4T1 cell line, in culture and in primary tumors. Additionally, we 
observed NPY-stimulated proliferation through Y5R activation, and signaling via ERK 1/2 
phosphorylation. Finally, we have shown that NPY is a potent chemoattractant acting 
through Y2R and Y5R activation. 
The expression of NPY receptors (Y1R, Y2R and Y5R) in the 4T1 cell line 
observed in the current study is congruent with others reporting the presence of NPY 
receptors in several different carcinomas including prostate (Magni & Motta, 2001), 
ovarian (Korner, Waser, & Reubi, 2004), and breast (Reubi, et al., 2001; Sheriff, et al., 
2010). Reubi et al. (Reubi, et al., 2001) reported expression of Y1R in 85% of the breast 
carcinomas sampled, while 24% were positive for Y2R. In all cases, Y2R positive tumors 
also expressed Y1R. Furthermore, in the same study, normal breast tissue expressed 
Y2R only. Y5R expression in breast cancer tumors was not investigated in the 
aforementioned study; however, a recent publication from Sheriff et al. (Sheriff, et al., 
2010) reported Y5R transcript and protein expression in several human breast cancer 
cell lines. In the 4T1 cell line we observed Y1R, Y2R, and Y5R expression and our Y1R 
and Y5R mRNA levels paralleled those recently reported by Sheriff et al. (Sheriff, et al., 
2010). Based on our immunohistochemical observations Y5R expression predominates 
over Y1R and Y2R expression in 4T1 cells and tumors.  
NPY has been shown to stimulate proliferation in prostate cancer (Ruscica, et al., 
2006), neuroblastomas (Kitlinska, 2007b) and breast carcinomas (Amlal, et al., 2006; 
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Sheriff, et al., 2010). In the current study we observed a concentration-dependent 
increase in proliferation with NPY treatment, with proliferation occurring in physiological 
concentrations of NPY (10-10-10-8 M) (Drell, et al., 2003). Additionally, Y5R agonist 
treatment induced a concentration-dependent increase in proliferation. Y1R (BIBP3226) 
or Y2R (BIIE0246) antagonism did not attenuate NPY-stimulated proliferation; however, 
Y5R blockade (using L-152,804) produced concentration-dependent attenuation of 
NPY’s effects. In support of these data, Y5R blockade inhibited the proliferative effects 
of the specific Y5R agonist treatment. This set of experiments illustrates the predominant 
role that the Y5R plays in NPY mediated proliferation in this cell line. These findings 
follow those reported in neuroblastomas and human breast cancer cells (Kitlinska, 
2007a; Sheriff, et al., 2010). Y5R activation has been shown to stimulate MAPK activity, 
leading to increased ERK 1/2 phosphorylation and cell proliferation (Pellieux, et al., 
2000; Sheriff, et al., 2010; Zukowska-Grojec, Karwatowska-Prokopczuk, Fisher, & Ji, 
1998). Sheriff et al. (Sheriff, et al., 2010), reported that Y5R activation led to an increase 
in pERK 1/2 in BT-549 cells, an effect that was inhibited by Y5R blockade. We observed 
a similar increase of pERK 1/2 levels after 2 minutes and 5 minutes of NPY treatment 
and Y5R agonist treatment, a response that could only be blocked by Y5R antagonism, 
further supporting that Y5R activation promotes NPY-stimulated proliferation.  
Neuropeptides have been implicated to be involved in the development of 
metastasis (Drell, et al., 2003). The migratory propensity of MDA MB-231 cells has been 
shown to increase when treated with NPY, a response that was mediated by Y5R 
activation (Sheriff, et al., 2010). In our current study, we observed that NPY acts as a 
concentration-dependent chemoattractant and it appears that NPY-mediated chemotaxis 
occurs through Y2R and Y5R activation. Accordingly, chemotaxis increased when cells 
were exposed to PYY3-36 (Y2R/Y5R agonist) and [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP 
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(Y5R agonist). Similar NPY-stimulated migration has been reported in endothelial cells 
as a result of Y2R and Y5R activation (Movafagh, et al., 2006).  
The immune system influences microenvironmental interactions between tumor 
cells and the host–tissue; such interactions mediate primary tumor development and 
play an important role in the metastatic cascade. Thus, in many human cell xenograft 
models in immunocompromised mice, metastatic development can often be variable and 
sometimes unpredictable (Bibby, 2004; Eccles, Box, Court, Sandle, & Dean, 1994). The 
4T1 murine mammary carcinoma represents a syngenic model that effectively 
metastasizes and exhibits similar metastatic characteristics to those clinically observed 
(Lin, et al., 1998; Pulaski & Ostrand-Rosenberg, 1998, 2001). Positive Y2R expression 
in this model contrasts the recent report that many human breast cancer cell lines lack 
this receptor (Sheriff, et al., 2010). Based on the work of others (Reubi, et al., 2001), we 
acknowledge that the Y2R effects observed in the current study may be relevant to a 
small subset of human breast carcinomas. However, our current findings highlight the 
complexity and heterogeneity of the NPY system in breast cancer. As it stands, this 
model enables the investigation of all three receptors (Y1R, Y2R, and Y5R) and their 
influence on breast cancer tumor formation.  
Overall, we report the presence of Y1R, Y2R and Y5R receptors in the 4T1 
murine breast cancer cell line for the first time. More importantly, we have shown that 
NPY (at physiological levels) is a potent proliferative and chemotactic agent in the 4T1 
cell line, acting through the Y5R and Y2R/Y5R respectively. Our findings support the 
accumulating evidence demonstrating the pathological contribution of NPY and its 
respective receptors in the development and progression of breast cancer. Given our 
current findings and previously reported interactions between stress, the sympathetic 
nervous system, the immune system and tumor cells, we propose the 4T1 cell line as a 
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syngenic model for future in vivo investigations addressing the integrated functional 
effects of NPY on breast cancer growth/progression and metastasis. 
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Chapter 3  
3 Neuropeptide Y promotes angiogenesis by increasing 
expression and secretion of VEGF from breast cancer 
cells  
Content from this chapter will be submitted as a manuscript to Microvascular Research.  
3.1 Introduction 
The involvement of stress-related factors to the initiation and progression of breast 
cancer has been a question of growing interest, with recent attention given to 
neurotransmitters of the sympathetic nervous system (norepinephrine: NE and 
neuropeptide Y: NPY). Through ß-adrenergic activation, NE has been shown to increase 
tumor growth, metastasis, and stimulate angiogenesis (Raju, Haug, Ibrahim, & 
Heyeraas, 2007; Shakhar & Ben-Eliyahu, 1998; Sloan, et al., 2010; Thaker, et al., 2006; 
Yang, et al., 2006). Congruently, NPY has been reported to increase proliferation and 
migration of breast cancer cells (Medeiros, et al., 2012; Sheriff, et al., 2010), and 
promote vacularization of neuroendrocrine tumors (Kitlinska, 2007; Kitlinska, et al., 
2005). 
Neuropeptide Y, a 36-amino acid peptide released by sympathetic nerves, is a potent 
trophic factor that can promote angiogenesis (Movafagh, Hobson, Spiegel, Kleinman, & 
Zukowska, 2006; Zukowska-Grojec, Karwatowska-Prokopczuk, Rose, et al., 1998). In 
mammals, angiogenesis occurs in exercised skeletal muscle (Burton & Barclay, 1986; 
Mai, Edgerton, & Barnard, 1970), ischemic tissue (Semashko, Song, Silverman, & 
Weinberg, 1985), the uterus during pregnancy (Lindenbaum, Langer, & Beach, 1991; 
Tamura & Greenwald, 1987), and during wound healing (Folkman, 1974; Knighton, 
Silver, & Hunt, 1981). In pathologies such as cancer, tumor development is dependent 
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on heightened angiogenic activity in order to supply the growing tumor with oxygen and 
nutrients. Angiogenesis is a multi-faceted process that involves many cytokine pathways 
that interact with the endothelium and smooth muscle. Under physiological 
concentrations, NPY has been shown to stimulate adhesion, migration, proliferation and 
capillary tube formation in human endothelial cells in vitro (Zukowska-Grojec, 
Karwatowska-Prokopczuk, Rose, et al., 1998). These responses were found to occur 
bimodially via Y1R, Y2R or Y5R activation (Movafagh, et al., 2006). The role of the Y2R 
is supported in vivo, where,Y2R knockdown mice exhibit compromised wound healing, 
associated with blunted angiogenesis (Ekstrand, et al., 2003; Lee, Grant, Movafagh, & 
Zukowska, 2003). Along the same line, Y2R knockdown mice display attenuated, 
hypoxia-induced retinal angiogenesis (Koulu, et al., 2004). Finally, exongenous NPY has 
been reported to increase tumor vascularization in neuroblastoma and Ewing’s sarcoma 
xenografts (Kitlinska, et al., 2005).  
Sympathetic neurotransmitters can function in a paracrine manner, stimulating the 
release of cytokines such as interleukin 6 (IL-6), interleukin 8 (IL-8), tumour necrosis 
factor α (TNFα), and vascular endothelial growth factor (VEGF) (Madden, Szpunar, & 
Brown, 2011; Tan, et al., 2007; Yang, et al., 2009). Activation of ß-adrenergic receptors 
on breast cancer cells and/or host stromal cells has been shown to cause the release of 
VEGF (Madden, et al., 2011). These responses occur via a cyclic adenosine 
monophosphate (cAMP) - protein kinase A (PKA) pathway, where ß-adrenergic 
receptors activation leads to increased cAMP, causing an activation of PKA, signaling for 
downstream changes in gene expression. NPY receptors belong to the family of G-
protein coupled receptors, which when activated cause inhibition of adenylate cyclase, 
leading to an decrease in cAMP (Zhu, Li, Toews, & Hexum, 1992).  
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As described above, previous studies demonstrate NPY’s potential to promote 
angiogenesis through its actions on vascular smooth muscle and endothelial cells 
(Movafagh, et al., 2006; Zukowska, Grant, & Lee, 2003) However, to our knowledge, 
whether activation of NPY receptors on breast cancer cells promotes VEGF secretion 
(i.e., paracrine) remains to be tested.  
The 4T1 breast cancer cell line is a syngeneic murine model of breast cancer, used by 
our group and others, that displays growth, metastatic and angiogenic patterns that 
parallel those of aggressive human cancers (Lin, et al., 1998; Prewett, et al., 1999). 
Recently, we reported the expression of NPY receptors (Y1R, Y2R, and Y5R) in 4T1 
cells, and found Y5R activation stimulated an increase in proliferation and Y2R and Y5R 
stimulated migration (Medeiros, et al., 2012). Using this model (in parallel with the MDA-
MB-231 human cell line), we tested the hypothesis that NPY promotes angiogenesis by 
augmenting expression and secretion of the pro-angiogenic factor VEGF within and from 
breast cancer cells.   
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3.2 Methods 
3.2.1 Reagents and Drugs 
Fetal bovine serum (FBS), culture media, DPBS and trypsin were purchased from 
Invitrogen (Invitrogen Canada Inc., Burlington, ON). Cell lysis buffer (M-PER Mammalian 
Protein Extraction Reagent) and protease inhibitors (Halt Protease Inhibitor Cocktail) 
were purchased from Pierce (Rockford, IL). For Western blot analysis, we used rabbit 
polyclonal antibodies, reactive with mouse and human VEGF (Cat no. ab46154, Abcam, 
Cambridge, MA, USA) and Beta Actin (Cat no. ab8227, Abcam, Cambridge, MA, USA). 
For secondary incubation we used antibody conjugated to horseradish peroxidase (goat 
anti-rabbit IgG, Cat no. 170-6515, Biorad, Hercules, CA, USA). NPY (non-specific YR 
agonist), [Leu31,Pro34]-Neuropeptide Y (Y1R agonist), Peptide YY (3-36) (Y2R agonist), 
[cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPancreatic Polypeptide (Y5R agonist), 
Scrambled NPY peptide (Negative control), BIBP3226 (Y1R antagonist), BIIE0246 (Y2R 
antagonist), and L-152,802 (L-152; Y5R antagonist), were from Tocris (Missouri, USA) 
3.2.2 Cell Culture 
4T1 cells, a gift from Dr. Fred Miller (Wayne State University, Michigan USA), 
were cultivated in high glucose Dulbecco’s Minimal Essential Medium (DMEM) 
supplemented with 10% sterile FBS. MDA-MB-231 cells were from the ATCC, cultivated 
with RPMI medium with 10% sterile FBS. Human umbilical endothelial vein cells 
(HUVEC) we purchased from Invitrogen (Invitrogen Canada Inc., Burlington, ON) and 
cultivated with Medium 131 (Invitrogen Canada Inc., Cat no. M-131-500, Burlington, ON) 
supplemented with Microvascular Growth Supplement (Invitrogen Canada Inc., catalog 
#S-005-25, Burlington, ON). All cells were incubated at 37ºC and 5% carbon dioxide. At 
approximately 80% confluency, cells were washed with DPBS and passaged using 
0.25% trypsin-EDTA treatment for dissociation.  
58 
 
3.2.3 Western blot Analysis - VEGF Expression 
Western blot analysis was used to test the effect of Y-receptor activation on 
VEGF expression in 4T1 and MDA-MB-231 cells. Cells were seeded in 60mm culture 
dishes at a density of 5x105 4T1 cells, and 1x106 MDA-MB-231 cells. After a 24hr 
incubation period cells were serum starved for 24hr, then treated with NPY (10-10-10-7 M), 
Y-receptor agonist (10-10-10-7 M), or NPY-scrambled peptide containing medium 
(negative control). Three receptor agonist treatments (Y1R, Y2R and Y5R) were tested 
with the 4T1 cells, whereas with MDA-MB-231 cells, given they only express the Y5R, 
experiments were only conducted with NPY and Y5R agonist treatments. Additionally, 
with the 4T1 cells blockade experiments were conducted BIBP3226 (Y1R antagonist), 
BIIE0246 (Y2R antagonist), and L-152,802 (L-152; Y5R antagonist) in order to support 
agonist experiments. After 24hr culture medium was removed, cells were washed three 
times in ice cold HBSS and then lysed in 500 µl lysis buffer containing protease inhibitor 
(104 mM AEBSF, 80 µM aprotinin, 2.1 mM leupeptin, 3.6 mM bestatin, 1.5 mM pepstatin 
A, 1.4 mM E-64). Cells were scraped and then lysed by sonication. Cell lysates were 
centrifuged for 15 minutes at 14,000 rpm at 4°C. Supernatant was collected and stored 
at -80°C until protein concentration was determined.  
Protein concentration was determined by Bradford assay (Bradford, 1976). Twenty 
micrograms of protein from each sample was loaded on a 4% to 12% gradient gel and 
separated by SDS-PAGE. Proteins were transferred at a constant voltage to 
polyvinylidene fluoride membranes. Membranes were blocked overnight in 5% milk in 
Tris-Buffered Saline + Tween20 (0.5%) (TTBS) at 4°C. Membranes were then incubated 
in primary antibody specific to VEGF in 5% milk TTBS at a concentration of 1:2000 at 
room temperature for 1hr. Membranes were washed in TTBS then incubated in 
secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit IgG, 
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1:20000) in 2% milk in TTBS for 1hr. Membranes were washed three times and bands 
were detected using an Immun-Star WesternC© chemiluminescent kit (Bio-Rad, 
Hercules, CA, USA) and imaged with the ChemiDoc XRS System (Bio-Rad, Hercules, 
CA, USA). To ensure equal loading, membranes were stripped, washed and then 
probed for beta actin (1:5000 primary antibody concentration, 1:20000 secondary 
concentration). Densitometric band analysis was performed with Quantity One 1-D 
Analysis Software (Bio-Rad, Hercules, CA, USA).   
3.2.4 VEGF Enzyme-linked immunosorbent assay (ELISA) 
VEGF secretion from 4T1 cells was measured in conditioned medium using 
ELISA (R&D Systems, Inc., Cat no. MMV00, Minneapolis, MN 55413, USA). Assays 
were conducted following manufacture’s protocol. Briefly, reagents were brought to room 
temperature. Standards and samples (50 µl) were pipetted in duplicate. After a 2hr 
incubation the plate was washed five times, and then 100 µL of Mouse VEGF Conjugate 
was added to each well. After 2hr incubation the plate was washed again, then 100 µl of 
TMB peroxidase substrate solution was added to all wells. The reaction was stopped 
after 30 minutes by adding the stop solution. The optical absorbance of each well was 
read at 450 nm (Bio-Rad Ultramark Microplate Imaging System, Bio-Rad, Hercules, CA, 
USA). The assay has a minimum detectable concentration of less than 3.0 pg/mL. 
(manufacturer's data). 
3.2.5 Conditioned Medium 
In order test if NPY stimulation of cancer cells would promote angiogenesis in 
vitro, we conducted endothelial tube formation assays with conditioned media from 4T1 
and MDA-MB-231 cells. Following a similar approach described for VEGF western blot 
experiments, cancer cells were seeded in 60mm culture dishes, and after a 24hr 
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incubation period, cells were serum starved for 24hr, then treated with NPY (10-10-10-7 M) 
or one of three Y-receptor agonists (10-10-10-7 M). NPY-scrambled peptide containing 
medium was used as a negative control. VEGF treated media was used as a positive 
control. 
3.2.6 Endothelial Tube Formation Assays 
Tube formation assays were conducted in 24-well tissue culture plates. Wells 
were coated with diluted Growth factor–reduced Matrigel (280 µL; 1:1 with DMEM, BD 
Biosciences, San Jose), then left to polymerize for 1hr at 37°C. Low passaged (< 5) 
Human umbilical vein endothelial cells (HUVEC) were cultured for no more then two 
weeks prior to tube formation assays. HUVEC were suspended in conditioned or non-
conditioned media and were then plated at a density of 7.5 x104 per well. Plates were 
then incubated for 6hrs at 37°C and 5% CO2. Wells were imaged (5 random 
images/well) using a light microscope at 5x magnification (Zeiss Axioskop, Nikon 
DXM1200 camera). The total number of branch points (BP) and complete endothelial 
networks (EN) were counted in each image and averaged per well.  Each 
treatment/condition was assayed in duplicate, and experiments were repeated 3-4 times. 
3.2.7 Statistical Analyses 
Statistical analysis was performed using GraphPad software. (Version 4.0a, 
GraphPad Software Inc) Data are presented as mean ± SEM. Statistical differences 
between treatments were evaluated by one-way ANOVA, followed by Tukey’s HSD test. 
The level of statistical probability was set at P<0.05.  
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3.3 Results 
3.3.1 VEGF Expression 
Western blot analysis was used to examine the effect of NPY receptor activation 
on VEGF expression in both the 4T1 and MDA-MB-231 cells. Twenty-four hours of NPY 
treatment (10-9M) caused a 52% ±14 increase in VEGF expression in the 4T1 cells 
compared to non-treated controls (Figure 3.1 A.). Similarly VEGF expression was 
significantly greater (61%±10) in NPY treated MDA-MB-231cells compared to non-
treated cells, at a concentration of 10-8 M (Figure 3.1 B.). Scrambled NPY peptide 
treatment had no effect on VEGF expression (p >0.05). 
  
 Figure 3.1 NPY stimulates an increase in VEGF expression. 
expression was observed in 4T1 (A.) and MDA
24hrs. In the 4T1 cells a 52%±14 increase (p <0.05) in
non-treated control cells was observed at 10
VEGF was observed at 
n=4,  * p<0.05, one-way ANOVA)
 
An increase in VEGF 
-MB-231 (B.) cells treated with NPY for 
 VEGF expression compared to 
-9 M NPY. A 61%±10 (p <0.05) increase
10-8 M NPY in the MDA-MB-231 cells  (p <0.05). (mean ± SE, 
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3.3.2 NPY Treated Conditioned Media  
Endothelial tube formation assays were conducted using conditioned media from 
4T1 and MDA-MB-231 cells. NPY treated conditioned media, at concentrations of 1010 - 
10-7 from 4T1 cells caused a significant increase in BP and EN (Figure 3.2 A.). Similarly, 
NPY treated CM from MDA-MB-231 elicited a 7-fold increase in BP and 9-fold increase 
in EN at 10-10 M, EN continued to increase at higher concentrations, up to 22-fold at 10-7 
M NPY (Figure 3.2 B.). Scrambled NPY treated conditioned media had no effect on BP 
or EN compared to control. The non-conditioned NPY media caused a modest increase 
in BP and EN, which was statistically less than the pro-angiongenic effects caused by 
NPY treated conditioned media.  
  
 Figure 3.2 NPY treated conditioned media promotes 
CM from 4T1 (A.) and MDA
complete endothelial networks. CM from 4T1 cells elicited a 2
fold increase in EN at 10
and 9-fold increase in EN at 10
(~22-fold at 10-7 M NPY). (mean ± SEM, n=4,  * p<0.05, one
Representative images depict response during control, scrambled NPY (10
(10-8M) and VEGF treatments.
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3.3.3 Y-Receptor agonist treated conditioned media 
In order to elucidate the contribution of each of the NPY receptors expressed in 
the 4T1 cell line (Y1R, Y2R and Y5R) to the pro-angiogenic response observed with 
NPY treated conditioned media, Y-receptor agonist experiments were conducted. 
Conditioned media from Y1R-agonist treated cells (Figure 3.3 A.) and Y2R-agonist 
treated cells (Figure 3.3 B.) had no effect on increasing in vitro angiogenesis. Whereas, 
conditioned media from 4T1 cells treated with Y5R agonist elicited a 3-fold increase in 
BP and an 8-fold increase in EN at a concentration of 10-9 M (p <0.05). 
 Figure 3.3 Effects of Y
angiogenesis.  4T1 cells were treated with Y1R agonist; [Leu31,Pro34]
agonist; Peptide YY (3-36) (B.) or 
hPP (C.), conditioned media from these experiments was tested on HUVEC. Y1R 
agonist, and Y2R agonist treatment had no effect on stimulating 
Y5R agonist treated conditioned media caused an increase in BP and EN. ). (mean ±
SEM, n=4,  * p<0.05, one
 
-receptor agonist treated conditioned media on 
Y5R agonist; [cPP1-7,NPY19-23,Ala31,A
in vitro 
-way ANOVA) 
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3.3.4 VEGF Release 
VEGF release was quantified in conditioned media from agonist experiments 
using ELISA. VEGF was elevated 2.5-fold in NPY treated conditioned media compared 
to non-treated controls. Y1R agonist treatment and Y2R agonist treatments had no effect 
on VEGF release, while Y5R agonist treatment cause a 2.5-fold increase at 10-9M. 
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Figure 3.4 Effect of Y-receptor stimulation on VEGF release. 4T1 cells were treated 
with NPY, Y1R agonist; [Leu31,Pro34]-NPY, Y2R agonist; Peptide YY (3-36) or Y5R 
agonist; [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]–hPP for 24hr. VEGF release was 
measured in conditioned media and compared to non-treated control conditioned media. 
NPY and Y5R agonist treatment induced a greater than two-fold increase in VEGF 
release. (Each experiment in duplicate) 
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3.3.5 Y-Receptor Stimulated VEGF Expression.  
 VEGF expression was quantified after Y-receptor agonist treatments. Western 
blot analysis revealed no effect of Y1R agonist (Figure 3.5 A.), or Y2R agonist (Figure 
3.5 B.) treatment on VEGF expression in 4T1 cells. Y5R agonist treatment cause a 2.5-
fold increase in VEGF expression in 4T1 cells compared to non-treated controls (Figure 
3.5 C.), and 1.6-fold increase in MDA-MB-231 cells (Figure 3.5 D.) (p<0.05). Additionally, 
a control experiment was conducted where Y-receptor antagonists were used in 
combination with NPY treatment. NPY treatment (10-9M) caused a 51% increase in 
VEGF expression, Y1R antagonism using BIBP3226 (10-5M) (Figure 3.6 A.) and Y2R 
antagonism with BIIE0246 (10-5M) (Figure 3.6 B.) had no effect in blocking the NPY 
stimulated increase in VEGF expression. Whereas the effects of NPY on VEGF 
expression were abolished when cells were treated with L152,802 (10-5M) (Figure 3.6 
C.) 
  
 Figure 3.5 Effect of Y
expression was probed for after 24hrs of Y
and Y2R agonist (B.) treatments had no effect on VEGF expression. Y5R ag
treatment caused in increase in VEGF expression in 4T1 cells (C.) and MDA
cells (D.) (mean ± SEM, n=3
 
 
-receptor agonist treatment on VEGF expression. 
-receptor agonist treatment. Y1R agonist (A.) 
-4, * p<0.05, one-way ANOVA). 
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Figure 3.6 The effect of Y-receptor blockade on NPY-stimulated VEGF expression. 
NPY (10-9M) stimulated a 51% increase VEGF expression in 4T1 cells compared to non-
treated controls. After preliminary experiments, Y1R antagonism using BIBP3226 (10-
5M) (A.) and Y2R antagonism with BIIE0246 (10-5M) (B.) had no effect in blocking the 
NPY stimulated increase in VEGF expression. Y5R antagonism with L152,802 (10-5M) 
(C.) blocked the effects of NPY on VEGF expression. (mean ± SEM, n=2) 
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3.4 Discussion 
In the current study we sought to elucidate the angiogenic properties of NPY in a 
breast cancer model.  Earlier studies, have demonstrated NPY can promote 
angiogenesis via direct stimulation of smooth muscle cells and the endothelium. 
However, in the current study we illustrate a paracrine mechanism in which NPY may be 
involved in the angiongenic cascade in breast cancer, as NPY receptor activation on 
breast cancer cells increased the expression and secretion of the pro-angiogeneic factor 
VEGF. 
VEGF, a member of the family of platelet-derived growth factors, is one of the 
primary pro-angiogenic factors that regulates angiogenesis in the tumor 
microenvironment. VEGF is subdivided into seven members, of which the ~45 kDa 
VEGF-A peptide, has been described as the major mediator of angiogenesis (Ferrara, 
2002), and its presence has been negatively correlated with the survival of certain 
cancers (Larcher, Murillas, Bolontrade, Conti, & Jorcano, 1998). It is well established 
that many cell types express VEGF, including stromal, endothelial and cancer cells. As 
well, in vitro studies have demonstrated that NE increases VEGF expression in MDA-
MB-231BR cells, through beta-adrenergic activation (Madden, et al., 2011; Tan, et al., 
2007; Yang, et al., 2009). However, we are the first to report NPY as a regulator of 
VEGF expression in 4T1 and MDA-MB-231 cancer cell lines.  
As measured from NPY-CM, we also observed that physiological concentrations 
of NPY evoked increased VEGF secretion from the 4T1 cell line. NPY has been shown 
to stimulate an increase in the secretion of VEGF from human dental pulp fibroblasts as 
well as other pro-angiogenic factors (El Karim, Linden, Irwin, & Lundy, 2009). Moreover, 
paracrine effects of NPY on VEGF release have been reported in ischemic skeletal 
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muscle (Lee, Michalkiewicz, et al., 2003). In breast cancer, NPY has been postulated to 
exert pro-angiogenic effects by directly acting on tumor vessels and/or endothelium, by 
promoting proliferation of smooth muscle cells and stimulating adhesion, migration, 
proliferation and capillary tube formation in endothelial cells (Tilan & Kitlinska, 2010; 
Zukowska-Grojec, Karwatowska-Prokopczuk, Rose, et al., 1998). Although these past 
studies reported that NPY exhibits direct angiogenic effects on vascular cells, we are the 
first to demonstrate that in breast cancer, NPY can promotes a pro-angiogenic 
microenvironment by working in concert with cancer cells as a paracrine system. 
Functionally, VEGF stimulates proliferation, sprouting, migration and capillary formation 
of endothelial cells (Otrock, Makarem, & Shamseddine, 2007; Papetti & Herman, 2002). 
In the current study, the VEGF concentration measured in CM from NPY treated cancer 
cells was more than 2-fold greater that non-treated controls. Our VEGF data is in 
congruence with data from our functional angiogenic assays, where we demonstrated 
that conditioned media from NPY treated cancer cells elicited a robust angiogenic 
response. This was observed as 2-fold increase in BP and 4-fold increase in EN from 
4T1 CM and MDA-MB-231 CM stimulated a 7-fold increase in BP and 9-fold increase in 
EN.  
Activation of ß-adrenergic receptors have been shown to increase VEGF 
expression on breast cancer cells (Madden, et al., 2011). In the current study, we sought 
to determine if activation of NPY receptors could elicit a similar response. Studies have 
shown the Y2R and Y5R to be involved in NPY’s proangiogenic responses in skeletal 
and smooth muscle, endothelial cells, retina and  neuroblastomas, (Ekstrand, et al., 
2003; Kitlinska, et al., 2005; Koulu, et al., 2004; Lee, Grant, et al., 2003; Zukowska-
Grojec, Karwatowska-Prokopczuk, Fisher, & Ji, 1998). We observed that Y5R activation 
stimulated an increase in VEGF expression, while Y1R and Y2R activation had no effect 
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on VEGF expression in the 4T1 cell line. Moreover, these findings were repeated in 
human MDA-MB-231 cells, which only express Y5R. Accordingly, NPY-stimulated 
increases in VEGF expression were blocked by Y5R antagonism using L152,802. The 
Y5R has received recent attention for its role as a mediator of proliferation and migration 
in breast cancer (Medeiros, et al., 2012; Sheriff, et al., 2010), however our current 
findings provide additional pathological implications of the Y5R in the context of breast 
cancer.  
In summary, we have determined that NPY functions as a paracrine system with 
cancer cells to promote angiogenesis. NPY Y5R activation of cancer cells led to 
increased expression and release of the VEGF from 4T1 and MDA-MB-231 cells. 
Although the objective of the current study was to examine the effects of NPY on VEGF 
expression and release from breast cancer cells, certainly future studies should consider 
other proangiogeneic factors such as IL-6, FGF, Ang1, Ang2, PDGF and MMP. 
Furthermore, future experiments blocking the VEGF pathway are required to confirm the 
responses observed in the current study. Additionally, the direct contribution of NPY to 
endothelial vessel formation must be accounted for in future control experiments.  
In conclusion, the results from the current study further support the 4T1 cell line 
as a syngeneic model for future in vivo investigations addressing the integrated 
functional effects of NPY on breast cancer angiogenesis. Moreover, NPY receptor 
expression and function should be considered in future development of therapeutics to 
inhibit tumor growth and angiogenesis.  
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Chapter 4  
4 The 4T1 breast cancer model, a syngeneic model of 
breast cancer for the functional study of the 
sympathetic neuropeptide Y system 
 
4.1 Introduction 
Neuropeptide Y (NPY), the most abundantly expressed peptide of the pancreatic 
polypeptide family in mammalian systems, exherts pleiotropic actions throughout the 
body. The 36-amino acid peptide is most widely expressed in the central and peripheral 
nervous systems, playing major roles in cognitive function, feeding behavior and 
cardiovascular regulation. NPY functions by activating a group of six G protein-coupled 
receptors (Y1R-Y6R) of which the Y1R, Y2R and Y5R are most abundantly expressed in 
humans, and have been most extensively studied (Michel, et al., 1998). In addition to 
being expressed in central and peripheral tissues, NPY receptors have been reported to 
be expressed in several cancers including neural crest tumors (e.g., neuroblastomas 
and pheochromocytomas) and epithelial malignancies such as ovarian, prostate and 
breast cancer (Kitlinska, et al., 2005; Kogner, Bjork, & Theodorsson, 1993; Korner & 
Reubi, 2008; Korner, Waser, & Reubi, 2004; Magni & Motta, 2001; Reubi, Gugger, 
Waser, & Schaer, 2001).  
Expression of the Y1R subtype was first reported to predominate in breast 
carcinomas (Reubi, et al., 2001). More recently, the expression of the Y5R was reported 
in several human cell lines (Sheriff, et al., 2010), where its activation was reported to 
promote cellular proliferation and migration. In support, we have shown similar 
proliferative and migratory effects of Y5R activation in the 4T1 murine breast cancer cell 
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line (Medeiros, et al., 2012). Additionally, Y5R activation in 4T1 cells has been found to 
stimulate an increase in VEGF expression and release in a concentration-dependent 
manner (Chapter 3), providing the first evidence for NPY’s involvement in tumor 
angiogenesis through this mechanism. 
In spite of growing evidence suggesting a functional role of NPY on the 
progression of breast cancer, to date, studies have been limited to in vitro 
experimentation. Syngeneic immunocompetent mouse models display tumor cell-host 
interactions and metastatic patterns that parallel those observed in cancer patients 
(Prewett, et al., 1999). The 4T1 murine breast cancer cell line is a well-established 
syngeneic model of breast cancer that has been used extensively to study anti-
metastatic and anti-angiogenic therapies (Lin, et al., 1998; Prewett, et al., 1999). 
Moreover, our recent in vitro findings demonstrating expression of NPY receptors, as 
well as the pro-proliferative, migratory, and angiogenic effects of NPY on 4T1 cells, 
supports the use of the 4T1 model for functional in vivo studies. 
In the tumor microenvironment the primary components of the sympathetic NPY 
system include sympathetic nerve fibers (source of NPY), NPY, NPY receptors and 
DPPIV and APP. Therefore, in the current study we sought to develop an in vivo model 
in which the components of NPY system (i.e., nerves, ligands and receptors) could be 
functionally studied. We first began by probing for sympathetic nerves and NPY in 4T1 
tumors. In order to determine the effects of the nerves on tumor growth and vascularity, 
we sought to develop a sympathetically dennervated tumor model. With our findings 
demonstrating a role for the Y5R in cell growth in this model, we then tested the effects 
of daily treatment with a Y5R antagonist on tumor growth. Finally, we attempted to 
develop a protocol for vascular imaging in 4T1 tumors using intravital video microscopy.  
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4.2 Methods 
4.2.1 Reagents and Drugs 
Fetal bovine serum (FBS), culture media, Hank’s Balanced Salt Solution (HBSS) 
and trypsin were purchased from Invitrogen (Invitrogen Canada Inc., Burlington, ON, 
Canada). For immunohistochemistry and Western blot experiments we used primary 
antibodies specific to mouse tyrosine hydroxylase (Cat no. AB152, EMD Millipore 
Corporation, Billerica, MA, USA), mouse NPY (Cat no. NPY11-A, Alpha Diagnostic Intl. 
Inc., San Antonio, Texas, USA), Anti- α-Smooth Muscle Actin - Cy3 (Cat no. C6198, 
Sigma-Aldrich Canada Ltd, Oakville, Canada), Anti-PECAM-1-FITC (Cat no. CBL1337F, 
EMD Millipore Corporation, Billerica, MA, USA). For immunohistochemistry secondary 
incubation we used Alexa Fluor® 594 Goat Anti-Rabbit (Cat. no. A-11012, Invitrogen 
Canada Inc., Burlington, ON, Canada). For Western blots we used secondary antibody 
conjugated to horseradish peroxidase (goat anti-rabbit IgG, Cat no. A0545, Sigma 
Aldrich, St. Louis, MO, USA). Lysis buffer (M-PER Mammalian Protein Extraction 
Reagent), protease inhibitors were purchased from Pierce (Rockford, IL, USA). 6-
Hydroxydopamine hydrobromide (6-OHDA) was purchased from Sigma (Cat no. H116, 
Sigma Aldrich, St. Louis, MO, USA), Triphase Accelerator Corp kindly provided the NPY 
Y5R antagonist TAC557 for tumor growth studies. 
4.2.2 Cell Culture 
4T1 cells, a gift from Dr. Fred Miller (Wayne State University, Michigan USA), 
were cultivated in high glucose Dulbecco’s Minimal Essential Medium (DMEM) 
supplemented with 10% sterile FBS. Cells were incubated at 37ºC and 5% carbon 
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dioxide. At approximately 80% confluency, cells were washed with HBSS and passaged 
using 0.25% trypsin-EDTA treatment for dissociation. 
4.2.3 4T1 Orthotopic Tumor Growth Characterization 
BALB/c mice, purchased from Charles River Laboratories (Saint-Constant, QC, 
Canada) at 6-7 weeks of age, were used for tumor growth studies. Animals were housed 
in the animal care facility at The University of Western Ontario. They were maintained on 
Harlan 2018, Teklad Global 18% Protein Rodent Diet and water ad libitum and kept on a 
12 hour light/dark cycle. All experimental procedures were carried out with the approval 
of the Council on Animal Care at The University of Western Ontario. 
After three passages, 4T1 cells were prepared for injection. Cells were washed 
and resuspended in sterile HBSS. The solution was filtered with a 40 µm cell strainer 
and cell viability was assessed by trypan blue staining and counting with a 
hemocytometer. The cell suspension was diluted to 103 cells/µl for injection. 
 Animals were anesthetized with isofluorine/oxygen gas mask (2-3% isofluorine, 1 L/min) 
and hair was removed from the lower abdominal region using commercial hair remover 
(Nair®). A sagittal cut (~1 cm) was made at the lower abdomen and skin was separated 
from the underlying muscle, to expose the underlying mammary fat pad. One hundred 
microliters (105 cells) of cell suspension was carefully injected into the right inguinal 
mammary fat pad. Wound clips were then applied to close the skin incision. Animals 
were returned to their cage for recovery and wound clips were removed 7 days later. 
Animals were then housed in cages without disturbance for 29 days. Twenty-nine days 
post-injection, all mice were sacrificed after induction of anesthesia using Ketamine (100 
mg/kg) and Xylazine (25 mg/kg) followed by cervical dislocation. Mammary tumors were 
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removed from each animal, sectioned in half, one half flash frozen in liquid nitrogen and 
the other fixed in 4% paraformaldehyde. 
4.2.4 Immunohistochemistry: Detection of Sympathetic Nerves 
and NPY 
Tumors were immersed in 4% paraformaldehyde solution in PBS, followed by 
paraffin processing and tissue embedding. Tumor tissues were sectioned (5µm 
thickness) and sequentially placed in triplicate on glass slides in staggered formation 
(with a non-specific binding control section on each slide). Following deparaffinization, 
tissues were placed in antigen retrieval buffer for 30 minutes at 75°C (10 mM sodium 
citrate buffer, 0.05% Tween-20, pH=6.0), washed in PBS, and blocked and 
permeabilized for 1hr in blocking solution (1.5% normal goat serum, 0.2% Triton-X 100 
(in PBS)) at room temperature. Sections were incubated overnight in primary antibody 
raised in rabbit specific to mouse tyrosine hydroxylase (TH) (Abcam Inc., Cambridge, 
MA, 1:1000) or NPY (Cat no. NPY11-A, Alpha Diagnostic International, San Antonio, TX, 
USA 1:500) diluted in 2% BSA in PBS at 4ºC. Following several washes in PBS 
Tween20, tissues probed with TH were incubated in goat anti-rabbit Alexa 594 (1:2000) 
and anti-mouse CD31 (PECAM-1) Fluorescein isothiocyanate conjugate (1:1000) to 
stain endothelial tissue, for 1 hour at room temperature. Slides probed for NPY were 
incubated in goat anti-rabbit Alexa 488 (1:2000) for 1 hour. All slides were washed and 
then treated with 100µl of 4’-6’-Diamidino-2-phenylindole (DAPI) in the dark for 5 
minutes. Finally, slides were then rinsed in PBS and cover-slipped with mounting 
medium Vectasheild (Vector Laboratories, Burlington, ON, Canada). Images were 
acquired using a Zeiss Axioplan 21E bright-field microscope (Carl Zeiss, Canada), 
ZeissAxioCam Hr camera (Carl Zeiss) with AxioVision 4.6 software (Carl Zeiss). 
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4.2.5 Sympathectomized 4T1 Tumor Model 
Mice were anesthetized with isoflurane gas (30% isoflurane). The lower abdomen was 
defurred and prepped with betadine 3 part preparation. A 1-1.5 cm linear incision was 
then made along the midline to lift the skin and blunt dissection was performed to 
expose the inguinal mammary fat pad. A 0.006mg/g dose of 6-OHDA or saline control 
was given by injection into the inguinal mammary fat pad (100 µl). Following injection, 
the incision was closed with wound clips and mice were returned to their cages, 
monitored during recovery and given a dose of subcutaneous fluids. Wound clips were 
removed within 3-4 days post surgery. Five days after the chemical dennervation, 4T1 
mammary inoculations were conducted as earlier described. Tumors growth was tracked 
for up to three weeks, after which mice were sacrificed; tumors were removed, weighed 
and sectioned in half for Western blot analysis (flash frozen) and immunohistochemistry 
(paraffin embedded). 
4.2.5.1 Western Blot Analysis of Tumor Sympathetic Innervation 
The effectiveness of 6-OHDA to ablate tumor sympathetic innervation was tested by 
Western blot analysis of TH expression in tumor lysates. One hundred milligrams of 
tumor tissue was immersed in ice-cold lysis buffer  (50 mM Tris, pH 7.5, 150 mM sodium 
chloride, 5 mM ethylene glycol tetraacetic acid, 0.5% sodium deoxycholate, 0.1% 
sodium dodecyl sulfate and 1% Triton-X 100) and mechanically homogenized. Lysates 
were centrifuged for 15 minutes at 14,000 rpm at 4°C. Supernatant was collected and 
stored at -80°C until protein concentration was determined.  
A Bradford assay (Bradford, 1976) was performed to determine total protein 
concentration of samples. Thirty-five micrograms of protein from each sample and a 
positive control (brain lysate) were loaded on a 4% to 12% gradient gel and separated 
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by SDS-PAGE. After electrophoresis, proteins were transferred at a constant voltage to 
polyvinylidene fluoride membranes. Membranes were blocked for 1hr in 5% milk in Tris-
Buffered Saline + Tween20 (0.5%) (TTBS) at 4°C. Membranes were then incubated in 
primary antibody specific to mouse TH (1:1000) in 5% BSA in TTBS at 4°C overnight. 
Membranes were washed in TTBS then incubated in secondary antibody conjugated to 
horseradish peroxidase (goat anti-rabbit IgG, 1:20000) in 2% BSA in TTBS for 1hr.  
Membranes were washed three times and bands were detected using an Immun-Star 
WesternC© chemiluminescent kit (Bio-Rad, Hercules, CA, USA) and imaged with the 
ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA). Membranes were stripped, 
washed then probed for β-actin (1:5000 primary; 1:20000 secondary). Densitometric 
band analysis was performed with Quantity One 1-D Analysis Software (Bio-Rad, 
Hercules, CA, USA).   
4.2.5.2 Immunohistochemistry: Tumor Muscular Vessel 
Quantification 
Tumors immersed in 4% formaldehyde in PBS were paraffin processed and paraffin 
embedded. Five µm sections were, deparaffinized, then placed in antigen retrieval for 50 
minutes at 70°C. Sections were washed in PBS then blocked and permeabilized at room 
temperature [2% bovine serum albumin (BSA), 0.2% Triton X (in PBS)]. After a PBS 
wash, tissues were incubated in primary antibody specific to mouse platelet endothelial 
cell adhesion molecule (PECAM-1-FITC conjugate) and α-smooth muscle actin (α-SMA-
rhodamine conjugate) ([PECAM-1] = 9.8µg/mL, α[α-SMA] = 4.975µg/mL] for two hours at 
room temperature. After several PBS washes, sections were incubated with Sudan 
Black Solution (1% in 70% ethanol) at room temperature for one hour. Then sections 
were rinsed in Hank’s Buffered Salt solution and then incubated in 4’,6-diamino-2-
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phenylndole, (DAPI; 12.5µg/mL) for ten minutes, after which slides were washed and 
mounted. 
Images were acquired at 20X magnification using a Zeiss Axioplan 21E bright-
field/fluorescence microscope (Carl Zeiss, Canada), ZeissAxioCam Hr camera (Carl 
Zeiss) with AxioVision 4.6 software (Carl Zeiss). For each tumor, five random fields of 
view were acquired for two sections. Muscular vessels immunoreactive for α-smooth 
muscle actin were counted by a blind observer and then averaged per animal. The mean 
number of muscular vessel per mm2 was calculated for the two different groups. 
4.2.6 Y5R Antagonist Tumor Growth Experiments 
The effects of Y5R antagonism on tumor growth were examined using the 4T1 tumor 
model. Tumor cells (5x103 cells in 100µl of PBS) were implanted as previously described 
in 5-6 wk old female Balb/c mice (n=28). Once tumors reached ~125-150 mm3 (day 17), 
mice were randomized into 4 groups based on tumor volume and body weights (n=7 per 
group). Each group received an oral daily dose (at 10 AM) of TAC557 (Trans isomer; 
provided by Triphase) (~ 0.1 ml) by gavage (22G feeding needle) at one of the following 
concentrations: 1) 5 mg/kg (1 mg/mL), 2) 30mg/kg (6mg/mL), 3) 90mg/kg (18mg/mL), 4) 
vehicle control. TAC557 was reconstituted in 0.1%CMC (low viscosity, Sigma, Cat no. 
P8074) + 0.08%tween-80 in water solution at a concentration of 30 mg/mL. The stock 
solution was diluted for each respective group and stored at 4˚C for the length of the 
study. Volume of drug was calculated based on animal body weight, which was 
measured daily. Drug or vehicle was administered until tumor volume exceeded 
1500mm3. When animals exhibited signs of distress (e.g., labored breathing, or body 
weight loss > 15%) they were sacrificed. Animal weights were monitored on a daily basis 
for the duration of the study. External caliper measures of tumors were taken every 
second day, which were used to calculate tumor volume using the modified ellipsoid 
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formula 1/2(Length × Width2). At the termination of the experiment, tumors were excised, 
weighed, and then sectioned in half. One half was flash frozen and the other was 
formalin fixed. Additionally, given high propensity for 4T1 cells to metastasize to the 
lungs, we also removed the lungs of all mice for qualitative analysis of metastatic 
lesions. 
4.2.7 Intravital Video Microscopy Tumor Model 
Mice were anesthetized with isoflurane gas (30% isoflurane), then placed supine 
on a custom-fabricated animal platform that uses conducted heat with animal 
temperature feedback to maintain esophageal temperature at 37°C. With the ventral side 
of the animal shaved and skin prepped, under microscopic guidance, a sagittal cut 
(~2cm) was made at the lower abdomen, and skin was carefully separated from the 
underlying muscle to expose the underlying mammary tumor. As we routinely observed 
vasculature and nerves originating from the femoral region, extra caution was taken to 
preserve this neurovascular supply. The skin flap was then gently reflected away from 
the mouse, spread evenly onto a custom-fabricated transparent Sylgard pedestal to 
approximate in situ dimensions, and pinned to secure edges. The preparation was then 
superfused continuously (4-5 ml/min) with a bicarbonate-buffered (pH, 7.4) physiological 
saline solution (PSS) equilibrated with 5% CO2 / 95% N2 and maintained at 34-35°C at 
the tissue. PSS was incubated in a thermally-jacketed 50-ml equilibration chamber 
positioned above the tissue, gravity-fed by a 2-litre reservoir containing control PSS. 
PSS was delivered from the chamber to the proximal edge of the tissue; effluent was 
aspirated continually ensuring constant flow of fresh PSS across the tissue. This 
preparation provided access to servicing tumoral vessels, surface vasculature and 
neural fibers. Once the preparation was complete, a tail vein injection of a flurorescent 
dextran (FITC or Rhodhamine; 0.05ml) could be administered (Varghese, et al., 2005). 
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Upon completion of microsurgical procedures, the preparation was transferred to the 
stage of the intravital microscope (Olympus BX51). The preparation was allowed to 
equilibrate for ~30 min, during which vascular networks were scanned. Dextran-filled 
vessels were excited with Mercury Vapor Short Arc light source (EXFO, X-Cite 120PC 
Q). Images were captured with a front-illuminated interline CCD camera (Qimaging EXi 
Blue) and viewed/collected using specialized imaging software MetaMorph 7.6. This 
preparation allowed for the collection of high-resolution video of flowing microvessels 
from which information regarding vessel diameter, vascular density and tortuosity could 
be gathered. 
4.2.8 Statistical Analysis 
Data presented as mean ± SEM. The Student’s t-test was used to compare tumor mass, 
TH expression and muscular vessels in control and 6-OHDA mice. A One-way ANOVA 
with a Tukey post hoc test was used to compare treatment groups in the Y5R antagonist 
tumor study. All statistical analyses, were performed using Prism (version 4, GraphPad 
Software Inc, La Jolla, CA, USA) and differences were accepted as statistically 
significant when p<0.05. 
4.3 Results 
4.3.1 4T1 Orthotopic Tumor Growth Characterization 
The growth rate of 4T1 tumors was tracked over a 35-day period (Figure 4.1). Tumor 
engraftment was successful in all 20 animals inoculated. Two weeks after tumor cell 
inoculation, tumor volumes were similar in all groups (150-250mm3), by the third week of 
tumor growth, we observed exponential growth of tumors in mice inoculated with 104, 
1.5x104 and 2x104 cells. 
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Figure 4.1 4T1 tumor growth curves. Growth rate of 4T1 tumors was tracked for up to 
35 days using caliper measures. Groups of mice (n=5/group) were inoculated with 
5x103, 104, 1.5x104, or 2x104 cells in the inguinal mammary fat pad. 
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4.3.2 4T1 Tumors Express Sympathetic Nerves and NPY  
Sympathetic innervation of the 4T1 mammary tumors was confirmed by 
immunofluorescence staining of sympathetic neural varicosities (tyrosine hydroxylase) of 
serial sections. We consistently observed sympathetic neural tissue that invaded deep 
into tumors surrounding tumor cells and tumoral arterioles (Figure 4.2 A.). Moreover, 
positive immunofluoresence revealed robust expression of NPY in 4T1 tumor sections 
(Figure 4.2 B.) 
  
A. 
 Figure 4.2 4T1 tumors are innervated by sympathetic nerves and express NPY. 
These cross-sectioned images (main image acquired at 16x, 
illustrate sympathetic neural invasion after 29 days of tumor growth. Tyrosine 
hydroxylase immunofluorescence was observed (Alexa 594
arterioles (endothelial cells stained with CD31
pad tumors (tumor cell nuclei: DAPI
immunofluorescence staining 
tumors (16x, tumor cell nuclei: DAPI
B. 
 
inset images at 
-red) in newly formed 
-FITC antibody) servicing mammary fat 
-blue). Panel B. depicts positive FITC
illustrating robust NPY expression in 4T1 breast cancer 
-blue, NPY: FITC,  scale bar: 100µm
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4.3.3 Sympathetically Dennervated Tumor Model 
We used 6-OHDA treatments to chemically ablate sympathetic innervation of the 
inguinal mammary fat pad of mice prior to tumor cell engraftment. Treatment with 6-
OHDA resulted in a 55% reduction in tumor mass compared to sham-treated controls 
(Figure 4.3 A.) Accordingly, TH expression was significantly reduced in 6-OHDA treated 
animals (Figure 4.3 B.). Immunohistochemical analysis was used to quantify tumoral 
muscular blood vessels in 6-OHDA treated and control animals. We observed a 
significant reduction in the number of muscular blood vessels in tumors from 6-OHDA 
treated mice compared to control (p<0.05, Figure 4.4). 
 
 
 
 Figure 4.3 The effect of chemical sympathectomy on tumor mass. 
reduced by 55% in tumor
treatment prior to tumor cell inoculation (A.). 
revealed a reduction in TH, supporting a reduction in sympathetic inn
tumors (B.). (n=5/group, mean ±
 
Tumor mass was 
-bearing mice which received 6-OHDA mammary gland 
Western blot analysis of tumor lysates 
erv
 SEM, *p<0.05, t-test) 
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ation of 6-OHDA 
 Figure 4.4 Effect of chemical sympathectomy on tumor muscular blood vessels. 
Immunofluorescence (Red; 
to quantify muscular blood vessels in control and 6
treatment with 6-OHDA prior to tumor inoculation caused a 46% reduction in muscular 
blood vessels in tumors compared to control tumors. 10 images per tumor were a
at 20X, and counted by a 
*p<0.05, t-test) 
 
α-smooth muscle actin, Green; CD31, Blue; 
-OHDA tumors. Mammary gland 
blind observer, scale bar = 100µm (n=4/group, mean ±
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4.3.4 The Effects of Y5R Antagonism on 4T1 Tumor Growth 
This experiment was performed over 47 days. Treatment with TAC557 
commenced 17 days after tumor cell inoculations; at this point all tumors were at a 
volume of >100mm3. Mice received treatment for an average of 21 ± 2 days in the 
control group, 22 ± 2 days in the 5mg/kg and 30 mg/kg groups and 23 ± 6 days in the 90 
mg/kg group (mean ± SD). Individual tumor growth curves are depicted in Figure 4.5. 
Mean tumor growth curves are represented in Figure 4.6 A. Final mean tumor volumes 
were: Control: 1631 ± 106 mm3, 5mg/kg: 1316 ± 137 mm3, 30mg/kg: 1237 ± 124 mm3, 
and 90 mg/kg: 1030 ± 154 mm3 (mean ± SEM, Figure 4). A significant reduction in mean 
tumor mass was observed in mice treated at 90mg/kg of TAC557 compared to vehicle 
treated controls. Mean tumor mass was 2.16 ± 0.25 g, 2.23 ± 0.22 g, 1.79 ± 0.25 g, and 
1.32 ± 0.14 g respectively (mean ± SEM, Figure 4.6 B.). Qualitatively, we observed a 
reduction in metastatic lesions in the lungs of mice treated with 90 mg/kg compared to 
vehicle treated controls (Figure 4.7). 
  
 Figure 4.5 Individual tumor growth curves of tumor
Y5R antagonist TAC557.
TAC557 at one of three dosages (5mg/kg, 30mg/kg, 90mg/kg), control animals received 
the drug vehicle. The onset of treatment commenced on day 17 (depicted by vertical 
black line) and continued up to day 46. T
Tumor volumes were calculated from caliper measures made every second day.
note, in the 90mg/kg group two animals exhibited outlier tumors and were sacrificed prior 
to conclusion of the study.
 
-bearing mice treated with the 
 Tumor bearing mice were treated daily via oral gavage with 
reatment duration was variable due to attrition. 
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Figure 4.6 Effect of Y5R antagonism on 4T1 tumor growth. 
treated daily via oral gavage with TAC557 at one of three dosages (5mg/kg, 30mg/kg, 
90mg/kg), control animals received the drug vehicle. The onset of treatment commenced 
on day 17 (depicted by vertical black line) and continued up to day 46, treatment 
duration was variable due t
measures made every second day. Mean tumor volumes are depicted in panel A. Panel 
B represents final mean tumor mass for each treatment group. Treatment with TAC557 
at 90mg/kg significantly attenuated
(n=7/group, *p<0.05, one
 
Tumor bearing mice were 
o attrition. Tumor volumes were calculated from caliper 
 tumor growth compared to vehicle treated controls 
-way ANOVA) 
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 Figure 4.7 Effect of Y5R antagonism on lung metastasis. 
all mice for qualitative analysis of me
highly metastatic 4T1 cells formed several lesions in the lungs of vehicle treated 
controls, an effect that appeared to be attenuated in mice treated with 90mg/kg of 
TAC557. 
 
Lungs were removed from 
tastatic lesions. As depicted in the photographs, the 
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4.3.5 Intravital Tumor Model 
This preparation provided access to servicing tumoral vessels, surface vasculature and 
neural fibers (Figure 4.8). Using flurorescent dextrans (FITC or Rhodamine) to label 
plasma, this preparation allowed for the collection of high-resolution video of flowing 
microvessels and provided images from which vessel diameter, vascular density and 
tortuosity could be rendered.  
 
 Figure 4.8 Establishing Intravital Microscopy 4T1 Model. 
model is well suited for intravital optical imaging. Within one week of inoculation tumors 
develop (tumor volume ~100mm
skin and muscles of the femoral region. This figure illustrates that when carefully 
microdissected, the skin of the lower abdominal region can be pinned out which allows 
for optical imaging of servicing vasculature, surface blood vessels and nerves using 
inverted microscopy.   
The highly angiogenic 4T1 
3). These tumors rapidly recruit vasculature from the 
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4.4 Discussion 
Accumulating evidence has supported a pathological role for NPY on breast 
cancer progression. To date, such findings have been limited to in vitro studies. Our 
group recently reported the expression of NPY receptors in the 4T1 breast cancer 
model. Moreover, we have observed pro-proliferative, migratory and angiogenic effects 
when 4T1 cells were exposed to NPY in vitro. As such, the impetus for the current study 
was to develop an in vivo model of breast cancer in which: 1) the components of the 
sympathetic NPY system could be characterized, 2) a functional role of NPY on tumor 
growth could be elucidated, and 3) a protocol for vascular imaging of 4T1 tumors using 
intravital video microscopy could be established. Herein, we demonstrated sympathetic 
neural innervation and NPY expression in 4T1 tumors. Additionally, when tumor 
sympathetic neural innervation was attenuated (via chemical sympathectomy), tumor 
growth and vascular development decreased significantly. Additionally, tumor growth 
was attenuated when tumor-bearing mice were treated with a Y5R antagonist. Finally, 
we established a protocol for intravital microscopy imaging of tumoral vasculature. 
Isolated by Dr. Fred Miller (Aslakson & Miller, 1992; Dexter, et al., 1978), the 
highly aggressive and invasive 4T1 murine mammary cancer cell line represents a 
syngeneic model that is highly tumorgenic, effectively metastasizes, and exhibits similar 
metastatic characteristics to those clinically observed (Lin, et al., 1998; Pulaski & 
Ostrand-Rosenberg, 1998, 2001). As a first step, we tracked tumor growth rates of 
varying number of implanted cells. Others have reported tumor development with 
implantation of as few as 5 x103 cells (Pulaski & Ostrand-Rosenberg, 1998). In our 
experiments, we also observed tumor development when 5x103 cells were inoculated 
into inguinal mammary fat pad. Although tumor growth curves were similar for the first 14 
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days of tumor bearing, growth rates from 104, 1.5x104 and 2x104 cell engraftments 
exhibited a more exponential growth profile after 21 days of tumor bearing and reached 
a terminal volume (>1500mm3, as per ethical approval) by 28 days for 2x104 cells, and 
35 days for 104 and 1.5x104, while tumors from 5 x103 cells engraftments were 
<1000mm3. As such, for drug/therapeutic studies that require a longer tumor growth 
period, engraftment of 5 x103 cells were deemed optimal. 
Nerve fibers of the SNS are the primary source of NPY to peripheral tissues and 
organs. Sympathetic nerves arising from the lateral and anterior cutaneous branches of 
the second to sixth intercostal nerves abundantly innervate the human breast providing 
the microenvironment of the breast with a constant outflow of sympathetic ligands 
(Fischer & Bland, 2007). Although an increasing number of studies have examined the 
effects of sympathetic neurotransmitters on cancer progression, few studies have 
examined the presence and or role of the sympathetic nerves in non-neurally derived 
cancers. To the best of our knowledge, in epithelial malignancies, the presence of 
sympathetic nerves has only previously been reported in a rat model of tongue cancer 
(Raju, Haug, Ibrahim, & Heyeraas, 2007). In the current study, we observed positive 
tyrosine hydroxylase immunoreactivity, providing evidence of tumoral sympathetic 
innervation, thus providing a supply of sympathetically derived neurotransmitters to 
tumor cells and blood vessels. Accordingly, we observed robust positive expression of 
NPY in tumors. Although, we did not colocalize TH immunoreactive nerves fibers with 
NPY expression in the current study, others have demonstrated colocalization of TH and 
NPY in human sympathetic neurons (Jarvi & Pelto-Huikko, 1990). Future studies should 
address the localization of NPY and its origin in the tumor environment.  
Sympathetic neurotransmitters can stimulate increased cell proliferation, thus it 
has been hypothesized that depleting neurotransmitter supply by ablating sympathetic 
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neurons may retard tumor growth. We tested this hypothesis by developing a chemically 
sympathectomized breast cancer model. Mammary tumors of mice treated with 6-OHDA 
prior to tumor cell implantations were 50% smaller then control animals. Similar findings 
were observed using bilateral sympathectomy, which cause a significant reduction in 
tongue tumors (Raju, et al., 2007). Similar effects have also been observed in a murine 
skin tumor model where sympathetically dennervating the skin caused a significant 
reduction in the growth of tumors (Romeo, et al., 1991),.  
Tyrosine hydroxylase is expressed in all sympathetic nerves and serves as the 
rate-limiting enzyme in the biosynthesis of sympathetic catecholamines (Udenfriend, 
1966). Increased TH expression provides index for number of nerve fibers, as well as 
increases in sympathetic nerve activity (Wong & Tank, 2007). As such, in the current 
study TH expression was measured in control and 6-OHDA treated mice. A local 
inguinal mammary injection of 6-OHDA was given in the current study at a concentration 
which has been reported to deplete the abdominal region of sympathetic nerves for up to 
35 days when administered intraperitoneally (Kvist-Reimer, Sundler, & Ahren, 2002). 
Although a significant reduction in TH expression was observed in 6-OHDA mice 
compared to controls, TH expression was still observed in 6-OHDA mice, indicating 
some level of tumor innervation. The release of pro-neurogenic factors from tumor cells 
such as nerve growth factor (NGF) may in part explain the presence of sympathetic 
nerves in 6-OHDA treated mice we observed. Treatment with murine NGF was found to 
reverse the tumor reducing effect of 6-OHDA in a murine neuroblastoma model (Fink & 
Mirkin, 1987). Thus, in spite of initial sympathetic dennervation of the mammary gland 
with 6-OHDA, elevated NGF released from 4T1 cells may have been involved in 
promoting neurogenesis during tumor development.  
104 
 
Elevated angiogenic activity is obligatory to tumor development. Several factors 
including sympathetic neurotransmitters interact with tumor cells and existing 
vasculature to stimulate increased tumor vascular supply. Thus, we examined the effects 
of sympathetic dennervation (6-OHDA) on tumor vascularity. We observed a significant 
reduction in the number of muscular blood vessels in 6-OHDA tumors compared to 
controls. Contrary to our findings, 6-OHDA treatment was reported to increase 
angiogenesis in a melanoma tumor model (Basu, et al., 2004). However, this was 
observed following systemic dose of 6-OHDA. Moreover, B16 melanoma cells have 
been previously reported to express and secrete catecholamines (Freed, Adinolfi, 
Laskin, & Geller, 1989), thus this tumor model may not best represent that of other 
carcinomas. Furthermore, the direct effects of catacholamines of NPY on the B16 cells 
were not examined in this study. In stressed mouse tumor models and pharmacological 
studies, elevated catecholamines and NPY have been associated with increased 
angiogenesis, supporting our findings in the current study (Kitlinska, et al., 2005; Raju, et 
al., 2007; Thaker, et al., 2006; Yang, et al., 2009).  
Our group and others have reported that Y5R activation stimulates breast cancer 
cell proliferation (Medeiros, et al., 2012; Sheriff, et al., 2010), however these findings had 
yet to be supported in vivo. Tumor-bearing mice treated with the Y5R-specific antagonist 
TAC557 exhibited slowed tumor growth compared to non-treated control animals. More 
remarkably, we observed a 39% reduction in tumor mass in animals receiving a daily 
oral dose 90 mg/kg of TAC557. Although treatment with 5 mg/kg and 30 mg/kg initially 
appeared to have a modest attenuating effect on tumor growth, final tumor measures 
indicated no effect with these dosages.  
From initial tumor growth experiments we determined 5x103 cells to be an ideal 
number of cells to engraft, that would consistently develop tumors and provide a tumor 
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bearing period long enough to test the effectiveness of TAC557. The 4T1 model is 
known to spread to lungs, lymphatics, liver, brain and bone (Aslakson & Miller, 1992; 
Pulaski & Ostrand-Rosenberg, 2001). We observed considerable metastatic lesions in 
the lungs. Qualitatively, we observed that control animals exhibited a greater number 
and size of lung lesions than animals in the 90 mg/kg. These findings were intriguing as 
Y5R activation has also been implicated with increases in chemotaxis and migration of 
breast cancer cells (Medeiros, et al., 2012; Sheriff, et al., 2010).  
These results provide promising data supporting TAC557 as tumor suppressing 
agent. Some considerations should be made for future studies when using the 4T1 
model and TAC557. First, treatment commenced 17 days after engraftment once all 
tumors were greater than 100 mm3. There was some variability in tumor volumes at the 
onset of treatment (100-300 mm3) that may have masked more significant effects 
TAC557. Given the rapid growth of 4T1 tumors, for future studies we recommend that 
mice should be excluded from experimental groups if their tumors have grown beyond 
an initial (pre-treatment) volume of 150mm3. This will allow for treatment to occur at a 
point prior to the exponential phase of tumor growth. Based on the data from the current 
study only 90 mg/kg was effective at attenuating tumor growth, therefore in future 
studies, animals should be treated with higher concentrations in order to elucidate any 
dose dependency of TAC557. Additionally, with such an aggressive cell line, a 
combination treatment study where tumor bearing mice are treated with chemotherapy 
and TAC557 may prove to augment the effects of TAC557 and increase the 
translatability of this model. 
Examining changes in tumor angiogenesis are most frequently conducted after 
the tumor has been excised through the use of histochemical techniques. Although quite 
important data can be gathered from histology such as vessel density and vessel 
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morphology, the use of intravital video microscopy provides a powerful tool for acquiring 
functional vascular data. In the current study we adapted intravital methodologies used 
for imaging of skeletal muscle (Al-Khazraji, Novielli, Goldman, Medeiros, & Jackson, 
2012; Jackson, Moore, & Segal, 2010) and applied them to the orthotopic 4T1 tumor 
model. In doing so, we developed a superfused tumor preparation (i.e., controlled salt 
and gas solution) in which the viability of the tumor tissue and vasculature was not 
compromised, thus tumor feed vessels, surface vasculature and neural fibers could be 
imaged over a period of up to 4 hrs. Using fluorescent dextrans (FITC or Rhodamine) to 
label plasma, this preparation allowed for the collection of high-resolution image 
sequences (at 15 frames per second) of flowing microvessels. Future post-processing 
and image analyses can now be developed in order to generate vascular diameter, 
density, branching, and vascular geometry data.  Moreover, this model could be adapted 
to collect functional data such as blood vessel perfusion, red blood cell flow and 
oxygenation of red blood cells. Although Doppler ultrasound can provide similar blood 
flow data, the use of our preparation would allow for such measures to be made in the 
presence of vasoactive compounds in real time. Imaging tumor surface vessels is, 
however, limited to tumors of volumes less than 200 mm3, larger tumors become difficult 
to image because of their spherical geometry. Moreover, objective specifications limit 
imaging depth thus deeper vasculature in larger tumors become challenging to image. 
However, servicing vasculature from the skin and femoral region may still be accessed 
and imaged in larger tumors. 
Overall the 4T1 breast cancer cell line provides an easily transplanted orthotopic 
breast cancer model that shares similar growth and metastatic characteristics of 
aggressive human breast cancers. Given our findings characterizing the components 
and function of the sympathetic of NPY system in this breast cancer model, we propose 
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the 4T1 model suitable for future functional studies examining the interactions between 
tumor cells, nerves, ligands and blood vessels. 
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Chapter 5  
5 Conclusions 
5.1 Thesis Summary 
 The work presented herein offers several novel and important findings 
contributing to the understanding the effects of NPY on the progression of breast cancer. 
In support of specific hypothesis 1), in Chapter 2 we reported expression of Y1R, Y2R 
and Y5Rs in 4T1 breast cancer cells and tumors. Additionally, in support of specific 
hypothesis 2), we observed NPY-stimulated proliferation in the 4T1 cells, which acted 
via Y5R activation signalling for phosphorylation ERK1/2. Finally, confirming specific 
hypothesis 3), NPY was found to be a potent chemoattractant acting through Y2R and 
Y5R activation., In Chapter 3, we tested the hypothesis that NPY would stimulate an 
increase in expression and secretion of VEGF from breast cancer cells, promoting in 
vitro angiogenesis. Our findings from this study revealed a novel mechanism by which 
NPY may contribute to tumor angiogenesis, as NPY receptor activation of breast cancer 
cells increased the expression and release of the pro-angiogeneic factor VEGF and 
promoted in vitro angiogenesis. 
Our in vitro findings from Chapter 2 and 3 led to the development of an in vivo 
tumor model in which the components of the NPY system (nerves, ligand and receptors) 
could be functionally studied in an immuno-intact model. We first demonstrated 
sympathetic neural innervation and NPY expression in 4T1 tumors. In order to test 
specific hypothesis 5) we developed a sympathetically dennervated tumor model using 
6-OHDA. We found that tumor growth and vascular development decreased significantly 
in mice with dennervated inguinal mammary fat pads. Given our findings in Chapter 2, 
that demonstrated Y5R mediated increases in 4T1 cell proliferation, we tested the 
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effects of oral daily Y5R antagonist (TAC557) treatment on tumor growth. In congruence 
with specific hypothesis 6), we observed a significant reduction of tumor growth in mice 
treated with a TAC557. As well, treatment with TAC557 appeared to reduce metastatic 
lesions in the lungs. Finally, by adapting methodologies used for imaging skeletal muscle 
(Al-Khazraji, Novielli, Goldman, Medeiros, & Jackson, 2012) we developed a protocol for 
optical imaging in 4T1 tumors using intravital video microscopy that would allow for 
servicing tumoral vessels, surface vasculature and neural fibers to be studied. 
5.2 Merit 
A growing body of evidence suggests that stress-related factors may contribute 
to the initiation, development and progression of breast cancer. NPY has recently been 
noted as such a factor, thus studies described in this thesis sought to elucidate 
mechanisms by which NPY may contribute to the disease. At present, few investigations 
have addressed the functional effects of NPY on breast cells and tumors. This 
dissertation provides novel evidence that NPY produces potent proliferative, migratory 
and angiogenic effects on breast cancer cells. 
Expression of NPY receptors has been reported in several human cancer cell 
lines (Sheriff, et al., 2010), however we are the first to show NPY receptor expression in 
a syngeneic 4T1 murine model of breast cancer (Medeiros, et al., 2012). This model is 
highly translatable, as it exhibits similar metastatic characteristics to those clinically 
observed (Lin, et al., 1998; Pulaski & Ostrand-Rosenberg, 1998, 2001). Positive Y1R, 
Y2R and Y5R expression was observed in this model. Interestingly, Y2R expression 
contrasts the recent report that many human breast cancer cell lines lack this receptor 
(Sheriff, et al., 2010). As such, the 4T1 model may be relevant to a small subset of Y2R-
expressing human breast carcinomas; nevertheless, our findings highlight the complexity 
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and heterogeneity of the NPY receptors in breast cancer. Based on the findings 
presented in this dissertation, the 4T1 model enables the investigation of all three 
receptors (Y1R, Y2R, and Y5R) and their influence on breast cancer tumor progression. 
Functionally, in this thesis, we have observed that physiological concentrations of NPY 
stimulates increases in proliferation and migration, and promotes pro-angiogeneic 
responses in 4T1 cells. Moreover, our work has exposed significant implications of Y5R 
activation in breast cancer.  
In Chapter 2, NPY-stimulated increases in cancer cell proliferation were 
mediated through Y5R activation, a response previously reported in neuroblastomas and 
human breast cancer cells (Kitlinska, 2007; Sheriff, et al., 2010).  In Chapter 4, we 
presented the first in vivo data supporting previous in vitro findings implicating Y5R 
activation in tumor growth. Tumor-bearing mice treated with the Y5R-specific antagonist 
TAC557 exhibited slowed tumor growth compared to non-treated control animals. We 
observed a 39% reduction in tumor mass in animals receiving a daily oral dose of 
TAC557 (90 mg/kg). These findings were in congruence with our data from Chapter 2, 
and provide promising support for the use of TAC557 as a tumor suppressing agent 
Neuropeptides have been implicated to be involved in the development of 
metastasis (Drell, et al., 2003). In Chapter 2, we observed that NPY acts as a 
concentration-dependent chemoattractant, where NPY-mediated chemotaxis occurs 
through Y2R and Y5R activation. Similar NPY-stimulated migration has been reported in 
endothelial cells as a result of Y2R and Y5R activation (Movafagh, Hobson, Spiegel, 
Kleinman, & Zukowska, 2006), and in MDA MB-231 cell by Y5R activation (Sheriff, et al., 
2010). Interestingly, in Chapter 4 we observed that tumor-bearing mice treated with the 
Y5R-specific antagonist TAC557 exhibited fewer metastatic lung lesions than vehicle 
treated controls (qualitative observation). These findings are quite intriguing as they 
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suggest potential involvement of the Y5R in metastatic progression/development, and 
further highlight the therapeutic benefits of TAC557. 
Although it has been established that NPY can promote angiogenesis via its 
direct effects on vascular smooth muscle and endothelial cells, the findings presented in 
chapter 3 provide a novel mechanism by which NPY can promote angiogenesis in breast 
cancer. The observation that Y5R activation of cancer cells increased expression and 
release of the VEGF from 4T1 and MDA-MB-231 cells provides the first report that NPY  
can promote a pro-angiogenic microenvironment by functioning in concert with breast 
cancer cells as a paracrine system.. These results support the merit of the 4T1 cell line 
as a syngenic model for in vivo investigations addressing the integrated functional 
effects of NPY on breast cancer angiogenesis, growth and progression and further 
support investigating the Y5R as a potential therapeutic target. 
Sympathetic nerves arising from the lateral and anterior cutaneous branches of 
the second to sixth intercostal nerves innervate the human breast (Fischer & Bland, 
2007), providing the microenvironment of the breast with a constant supply of 
sympathetic ligands. Accordingly, in Chapter 4, for the first time, we demonstrated the 
presence of sympathetic nerves and NPY in an orthotopic 4T1 breast cancer model. 
Additionally, we demonstrated a functional role of sympathetic nerves on tumor growth 
and vascularity, by chemically attenuating sympathetic innervation of mammary fat pads. 
Mammary tumors of mice treated with 6-OHDA prior to tumor cell implantations were 
50% smaller then control animals. Similar effects of sympathectomy have been reported 
in tongue (Raju, Haug, Ibrahim, & Heyeraas, 2007) and skin tumors (Romeo, et al., 
1991). We also observed a significant reduction in the number of muscular blood vessels 
in 6-OHDA tumors compared to controls. These findings highlight a role for sympathetic 
nerves, catecholamines and neuropeptides in tumor growth and angiogenesis.  
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Functional data from Chapters 2, 3 and 4 served as impetus for developing the in 
vivo orthotopic intravital tumor model described in Chapter 4. The use of intravital video 
microscopy provides a powerful tool for acquiring functional vascular data, which cannot 
be acquired using histological techniques. A protocol was developed by adapting 
intravital methodologies used for imaging of skeletal muscle (Al-Khazraji, et al., 2012) to 
the orthotopic 4T1 tumor model. In doing so, we have now established a physiologically 
viable superfused tumor preparation in which tumor feed vessels, surface vasculature 
and neural fibers can be imaged under physiological in situ conditions.  Overall, this 
model can be used to collect valuable real-time hemodynamic data such as overall 
tumor perfusion, microvascular blood flow and red blood cell oxygenation, functional 
vascular density, and vessel tortuosity.  
5.3 Limitations and Assumptions 
5.3.1 Chapter 2 
Experiments within this thesis have been primarily conducted using the 4T1 
murine breast cancer model, and as such, the translatability of our findings to the human 
condition could be considered limited. However, syngenic models are commonly 
described as basic tools for translational research as they represent a more 
physiologically complete model. Often tumor and metastatic development of human cell 
xenograft models in immunocompromised mice are quite variable and sometimes 
unpredictable (Bibby, 2004; Eccles, Box, Court, Sandle, & Dean, 1994). Unlike human 
cell xenograft models, the 4T1 model provides an immuno-intact environment, and given 
the cross-talk between the immune system and SNS, the 4T1 model represents a 
physiologically relevant breast cancer model in which nerves, ligands, tumor cells and 
blood vessels can be studied. 
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Positive Y2R expression in the 4T1 model contrasts the recent report that many 
human breast cancer cell lines lack this receptor (Sheriff, et al., 2010). Based on the 
work of others (Reubi, Gugger, Waser, & Schaer, 2001), we acknowledge that the Y2R 
effects observed in our work may be relevant to a small subset of human breast 
carcinomas. However, our current findings highlight the complexity and heterogeneity of 
the NPY system in breast cancer. Thus, this model enables the investigation of all three 
receptors (Y1R, Y2R, and Y5R) and their influence on breast cancer tumor progression.  
5.3.2 Chapter 3 
The objective of Chapter 3 was to examine the effects of NPY on VEGF 
expression and release from breast cancer cells. Although we determined that NPY 
functions as a paracrine system with cancer cells to promote angiogenesis by increasing 
VEGF expression and secretion, we did not test whether other pro-angiogenic factors 
respond similarly. It is possible that expression and secretion of factors such as IL-6, 
FGF, Ang1, Ang2, PDGF and MMP, could also be stimulated by NPY receptor 
activation. Additionally, expression and release of such factors could be dependent on 
receptor subtype-specific interactions. Functional experiments in this study were limited 
to in vitro angiogenesis assays, thus recapitulating similar NPY-mediated effects in vivo 
would strengthen and increase the impact of findings reported in Chapter 3. 
5.3.3 Chapter 4 
In Chapter 4 we sought to develop an in vivo model in which the components of 
the NPY system (i.e., nerves, ligands and receptors) could be studied functionally. The 
presence of these components in 4T1 tumors  was comfirmed by positive TH and NPY 
immunoreactivity. Although experiments we not conducted to confirm that TH 
immunoreactive nerves fibers were colocalized with NPY, others have reported a 
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positive correlation between TH and NPY in human sympathetic neurons (Jarvi & Pelto-
Huikko, 1990). In this chapter we also developed a sympathetically dennervated tumor 
model using 6-OHDA in order to determine the effects of the nerves on tumor growth 
and vascularity. Although we did find 6-OHDA treatments caused a reduction in tumor 
growth and vascularity, we cannot definitively conclude that it was due to a reduction in 
sympathetic neurotransmitters, as these were not quantified in the study. Reductions in 
TH expression of 6-OHDA tumors do however support a reduction in neurotransmitters. 
Additionally, although not the objective of this thesis, throughout our experiments we did 
not examine the effects of NE on proliferation, migration or angiogenesis. As such, we 
cannot rule out NE as a potential mediator of the findings in the 6-OHDA model.  
In Chapter 4 we tested the effects of an orally administered Y5R antagonist (TAC557) on 
tumor growth. Although TAC557 exhibited promising tumor suppressing properties, we 
found that only a dose of 90 mg/kg was effective at attenuating tumor growth, thus from 
this study we could not conclude dose dependency of TAC557. Future studies are 
required to elucidate to peak tolerable dosing and any dose dependency effects. 
Additionally, because 4T1 cells are known to spread to the lungs (Aslakson & Miller, 
1992; Pulaski & Ostrand-Rosenberg, 2001), we also qualitatively examined lung 
metastatic burden in this study. Although the impetus for the TAC557 study was to test it 
as a tumor suppressing therapy, we were quite intrigued by clear differences in lung 
metastatic lesions between control and TAC557 treated mice. These findings certainly 
merit subsequent studies designed to test the effects on TAC557 on metastasis. 
5.4 Future Directions 
Breast cancer remains the most frequently diagnosed cancer among females, 
affecting thousands of women each year. Although extensive research has reduced 
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death rates significantly over the past thirty years, many of the underlying mechanisms 
that drive the progression of this disease remain to be defined. Stress and stress-related 
factors have long been thought to be associated with the development and progression 
of cancer, as epidemiological studies have correlated elevated stress with poor 
prognosis and/or survival of cancer patients (Ben-Eliyahu, 2003). Accumulating evidence 
suggests a pathological role for sympathetically released neurotransmitters, as their 
influences increase in the response to stress and they exhibit deleterious mitogenic, 
chemotaxic and angiogenic properties on cancer cells (Cole & Sood, 2012; Ruscica, 
Dozio, Motta, & Magni, 2007). Expression of NPY receptors in several breast cancer 
cells (Korner & Reubi, 2007; Medeiros, et al., 2012; Sheriff, et al., 2010) and a neural 
supply of NPY to the breast has prompted the study of NPY as an endogenous 
pathological factor, contributing to the progression of breast cancer. Overall, this 
dissertation provides evidence that NPY elicits proliferative, migratory and angiogenic 
effects on breast cancer cells, and describes a viable in vivo model for functional studies 
examining the relationship between sympathetic nerves, neurotransmitters, cancer cells 
and blood vessels on tumor progression. 
The work described herein provides the foundation and impetus for several future 
studies. For example, using qPCR, we recently found NPY and TH mRNA transcripts in 
4T1 cells.  Although not uncommon in neurally-derived cancers, to our knowledge such 
an intriguing finding has yet to be reported in any type of breast cancer. Whether mRNA 
transcripts for NPY and TH will translate to expression and release of NPY and NE 
remains to be tested. Such a finding would lead to several interesting questions 
regarding a potential NPY/NE autocrine system in the 4T1 model. Additionally, as 
previously mentioned, we did not explore the effects of NE on 4T1 cells, and whether NE 
or any other sympathetic neurotransmitter has any effects on 4T1 cells and tumors 
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remains to be addressed. Furthermore, since NE and NPY have been shown to act 
synergistically, an additional question to be asked is whether NE and NPY (or other 
neurotransmitters) exert any synergistic or antagonistic effects on 4T1 cells. The 
expression of multiple NPY receptors in 4T1 cells and other breast cancer cells also 
highlights the potential role for the proteolytic enzymes DPPIV and APP in tumor 
progression. Differences in their proteolytic activity on NPY would promote changes in 
the availability or NPY2-36, or NPY3-36 (which have affinity for Y2R and Y5R) and may 
impact cell proliferation, migration, and angiogenesis.  
We have shown the presence of sympathetic nerves in 4T1 tumors; however, 
how these nerves develop, and if they function as normal peripheral sympathetic nerves 
are important questions to be addressed. Measuring sympathetic nerve output to 
mammary tumors would provide valuable functional insight on the neural contribution to 
tumor development. Additionally, testing whether neural development is obligatory or 
potentiates a greater angiogenic response could reveal potential therapeutic targets 
such as NGF neutralizing antibodies. 
In breast cancer, as in other cancers, the primary tumor is often treatable; it is the 
spread of cancer cells from the primary tumor to secondary sites that accounts for the 
majority of cancer fatalities. Although we did find some data that would implicate a role 
for NPY in metastasis, many questions remain, such as testing the involvement of NPY 
(and other neurotransmitters) at all steps of the metastatic cascade (invasion, 
intravasation, circulation, arrest and extravasation). In Chapter 2 we showed that NPY 
exherted chemotactic effects on 4T1 cells. Thus, a question of particular interest and 
clinical significance would be; Do NPY receptor-expressing cancer cells extravasate to 
sites of high sympathetic innervation and neurotransmitter supply? (i.e. lymphatics or 
brain). 
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Finally, sympathetic neurotransmitters are acutely and chronically modulated by 
stressful insults (physical, emotional, psychological, physiological), thus a few groups 
have examined the role of different types of stress on tumor progression and metastasis, 
however much remains to be understood. The 4T1 model represents an immune-
competent model in which the effects of both deleterious (i.e psychological) or beneficial 
(i.e exercise) stress paradigms could be examined on tumor progression/ metastasis. 
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